Successful Development of a Flow Cytometric Assay to Analyze Cytokine-Induced Phosphorylation Pathways [CIPP] Within Peripheral Blood Leukocytes by Montag, David Thomas
 
 
SUCCESSFUL DEVELOPMENT OF A FLOW CYTOMETRIC ASSAY TO ANALYZE 
CYTOKINE-INDUCED PHOSPHORYLATION PATHWAYS [CIPP] WITHIN 
PERIPHERAL BLOOD LEUKOCYTES 
 
 
 
 
 
 
 
by 
 
David T. Montag Jr. 
 
B.S., Case Western Reserve University, 2003 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of  
 
the School of Engineering in partial fulfillment 
 
of the requirements for the degree of  
 
Master of Science 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2006 
 
 
 
 ii
 
 
UNIVERSITY OF PITTSBURGH 
 
SCHOOL OF ENGINEERING 
 
 
 
 
 
 
 
This thesis was presented 
 
by 
 
 
David T. Montag, Jr. 
 
 
It was defended on 
 
July 6, 2006 
 
and approved by 
 
Partha Roy, Ph.D., Department of Bioengineering 
 
Albert D. Donnenberg, Ph.D., Department of Medicine 
 
Thesis Advisor:  Michael T. Lotze, M.D., Departments of Surgery and Bioengineering 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii
 
 
 
 
 
SUCCESSFUL DEVELOPMENT OF A FLOW CYTOMETRIC ASSAY TO ANALYZE 
CYTOKINE-INDUCED PHOSPHORYLATION PATHWAYS [CIPP] WITHIN 
PERIPHERAL BLOOD LEUKOCYTES 
 
 
David T. Montag, Jr., M.S. 
 
 
University of Pittsburgh, 2006 
 
 
 
 
Current strategies designed to assess cells in the peripheral blood are limited to evaluation of 
phenotype or delayed measurement [>6 hours] of function, usually quantifying cytokine 
production, cytolytic activity, or response to antigens.  Furthermore, these assays often do not 
assess the individual cell types comprising peripheral blood, instead providing a bulk-readout for 
the total population.  We reasoned that functional abnormalities in distinct peripheral blood cells, 
which act as immune sentinels capable of rapidly reacting to various injurious agents while 
circulating throughout the body, could serve as migratory biomarkers, reflecting pathological 
environs that cells experience in the setting of inflammatory states, including cancer.  Two major 
pathways regulating immune responses are the JAK/STAT and MAPK pathways.  These 
pathways are initiated by ligand-receptor binding, and are rapidly propagated by subsequent 
protein phosphorylation cascades.  Additionally, these pathways are often abnormally activated 
within cancer cells themselves.  We applied flow cytometric strategies, evaluating the brief 
application of cytokines in vitro to interrogate the early phosphorylation events of these signaling 
 iv
pathways in normal peripheral blood mononuclear cells (PBMC).  Individual cytokine doses and 
time intervals of treatment were assessed to identify conditions useful in a clinical laboratory and 
as an initial goal, to induce maximal phosphorylation.  Surprisingly, all of the STAT proteins 
assessed and ERK1/2 are maximally phosphorylated within 15 minutes in human PBMC, simply 
following addition of cytokines alone.  Within two hours, cells typically return to their basal 
phosphorylation states.  Confirmation of these results was achieved by Western blotting.  
Increased phosphorylation usually correlated with increased concentrations of individual 
cytokines.  Furthermore, we developed conditions to enable simultaneous staining of cell surface 
proteins, identifiable with distinct PBMC subpopulations: CD4, CD8, CD14, CD19, and CD56, 
together with intracellular phosphorylated proteins.  Of the permeabilizing conditions tested, 
75% methanol enabled superior simultaneous detection of both cell surface and intracellular 
epitopes.  Using this technique, we were able to identify differential responsiveness between 
individual cell types.  These strategies will enable robust development of simple blood analyses 
to identify normal activation as well as impairments in STAT and MAPK signaling pathways 
associated with various human disease states including acute and chronic inflammatory 
conditions throughout clinical immunology. 
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1.0 INTRODUCTION 
 
 
“The engineer is the key figure in the material progress of the world.  It is his engineering that 
makes a reality of the potential value of science by translating scientific knowledge into tools, 
resources, energy, and labor to bring them into the service of man … To make contributions of 
this kind the engineer requires the imagination to visualize the needs of society and to appreciate 
what is possible as well as the technological and broad social age understanding to bring his 
vision to reality.” – Sir Eric Ashby (1958) 
 
In the setting of most diseases, including infection [1-4], autoimmunity [5, 6], and cancer [7-11], 
analysis of cellular function within the peripheral blood provides clinicians and scientists with 
important insights into pathobiology.  Most functional assays applied to peripheral blood 
mononuclear cells (PBMC), however, are tedious, require long culturing periods and separation 
of cellular subsets, which could introduce artifacts, falsely representing native, in vivo function 
[12, 13].  Functional assays developed for clinical application should be designed to be robust 
and rapid to quickly screen patient samples, thus reducing the time interval during which cells 
are manipulated.  Some of the earliest events identified during complex biologic responses are 
those associated with proximal signaling events, whereby individual cellular pathways are 
activated by protein phosphorylation cascades that dictate distal events including cytokine 
production, oxidative burst, and cytolytic activity [14].  Thus, an assay to detect these rapid 
changes in cellular function following a specific stimulus may prove useful in the clinical setting.   
By utilizing recently developed reagents, phosphorylation state specific antibodies 
(PSSAs), it is possible to distinguish between phosphorylated and unphosphorylated proteins 
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belonging to important signaling pathways.  Such antibodies have previously been employed in a 
variety of applications, including more conventional biochemical assays such as Western 
blotting, and in more recent assays, including flow and imaging cytometry, as well as protein 
microarrays [15-20].  Of these applications, only flow and imaging cytometry are capable of 
analyzing individual cells, particularly in complex mixtures.  However, imaging cytometry 
analyzes cells at a somewhat slower rate than conventional flow cytometry, requires the 
capability of managing large data files with multiple detailed images acquired, and is best suited 
for adherent cells.  In contrast to cytometry, Western blots and protein microarrays provide an 
average result spanning an entire population of cells, perhaps best applied with relatively 
homogenous cell populations.  As a result, we evaluated flow cytometric strategies as a platform 
for our analysis of phosphorylated proteins within PBMC, a complex population of largely non-
adherent cells.  
Two major signaling pathways, the JAK/STAT and MAP kinase pathways, are central to 
the regulation of many vital cellular processes and controlled by protein phosphorylation 
cascades [21-26].  Furthermore, abnormal activation, or phosphorylation, of many proteins 
belonging to these pathways within cancerous cells, including malignancies associated with 
PBMC, is extensively documented in the scientific literature [27-35].  Interestingly, the main 
stimuli activating the aforementioned pathways are cytokines, growth factors, and cellular stress, 
which are often abnormally expressed or elevated within the serum in the setting of cancer [36-
43] or other inflammatory disorders.  As a result, we reasoned to believe that evaluation of non-
malignant PBMC residing in patients with a  variety of acute and chronic inflammatory 
conditions will display altered signaling pathways, providing scientists and clinicians with a 
useful and rapidly available diagnostic tool.   
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Because the application of flow cytometry to phosphorylated signaling proteins is a 
relatively novel strategy, we first characterized the phosphorylation of several important 
members of the JAK/STAT and MAP kinase signaling pathways: STAT1, STAT3, STAT5b, 
STAT6, p38 MAPK, and ERK1/2, following the brief application of appropriate stimuli in a 
dose and time-dependent manner.  By taking advantage of the fact that monocytes and 
lymphocytes typically have different light scattering properties, we were able to analyze results 
within each of these populations separately without the use of additional reagents.  Once suitable 
stimulation conditions were established, we successfully developed methodology to 
simultaneously label intracellular phospho-epitopes and cell surface proteins used to identify 
subpopulations of cells within the PBMC: CD4+ or CD8+ T cells, CD14+ monocytes, CD19+ B 
cells, and CD56+ NK cells.  This strategy allowed us to examine differential signaling within 
individual PBMC subsets following activation with various stimuli.   The methods developed in 
this thesis provide an excellent stepping-stone for more in-depth studies regarding cell activation 
and its involvement in various diseases. 
With regard to the organization of this thesis, the layout is as follows.  The introductory 
chapter summarizes the essential aspects of flow cytometry, various assays used to study protein 
phosphorylation, including Western blotting, protein microarrays, flow cytometry, and imaging 
cytometry, the JAK/STAT and MAP kinase signaling pathways, signaling abnormalities within 
hematological malignancies, alterations in cytokine expression associated with tumors, and 
defects in “normal” PBMC within the setting of cancer.  Chapter three outlines the two specific 
aims of this thesis, including our hypotheses for each of them individually.  In chapters four and 
five, we introduce our reasoning for pursuing specific aims one and two respectively, followed  
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by materials and methods used to accomplish each and the ensuing results and discussion 
sections.  In conclusion, a summary of the results from each of the aims is provided, in addition 
to implications of these findings and directions proposed for future investigation.  
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2.0 LITERATURE REVIEW 
 
 
 
 
2.1 FLOW CYTOMETRY 
 
 
Flow cytometry is an invaluable technique used to rapidly analyze large numbers of cells from a 
wide variety of sources.  Provided the original sample is a single-particle suspension, cytometers 
can detect particles ranging from one centimeter to ten angstroms in size (i.e., single-cell 
organisms to individual molecules) [44].  Due to its usefulness and broad utility, flow cytometry 
is applicable in a wide range of fields such as clinical medicine, pharmacology, toxicology, 
bacteriology, virology, environmental sciences, and bioprocess monitoring [45].  In contrast to 
traditional methods that provide an average measurement for an entire population, flow 
cytometric data enables resolution of individual particles resident within a population.  Naturally, 
this is desirable when analyzing complex, heterogeneous samples, such as peripheral blood, 
where information from rare subpopulations would be lost if a population-based average was 
obtained.   
 In principle, a flow cytometer is designed to acquire light-scatter and fluorescence 
measurements that are associated with components or characteristics of individual cells.  To 
achieve these measurements, a flow cytometer employs lasers, fluidics, optics, detectors, 
measuring circuits, and computer electronics.  Briefly, a single cell suspension is injected into a 
flow cell, where a surrounding stream of sheath fluid hydrodynamically focuses it into the 
central most region of a laser beam oriented orthogonal to the direction of flow, allowing cells to 
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Figure 1. Typical setup for a three-color cytometer with two scatter detectors [44] . 
pass through one at a time.  When the laser makes contact with a cell, the incident light is 
scattered.  Detectors are arranged to collect forward scattered and right-angle side scattered light.  
Forward scatter relates to the size of the cells passing through the laser while side scatter relates 
to their granularity and internal complexity.  Using these scatter parameters alone, individual 
populations of cells may be identified within complex mixtures.  If the cells are labeled with 
fluorescent dyes or antibodies conjugated to fluorophores, particular components of the cells 
may also be detected.  Dyes or fluorophores excited by the laser will emit fluorescence, which 
can be captured by additional optical detectors in combination with optical filters to select for 
specific wavelengths.  Following contact with the optical detectors, photons are converted to an 
electronic signal, which is then digitized by measuring circuits, and sent to a computer for data 
analysis.  The optical components of a typical three-color flow cytometer are illustrated in Figure 
1 [44].  As one may imagine, current cytometers have the capability of simultaneously measuring  
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more than just three fluorescent parameters by utilizing a combination of different fluorophores, 
applying highly evolved hardware and software.  Some high-end, recently developed cytometers 
are capable of measuring up to 17 different fluorescent parameters and two scatter parameters 
[46].  As a starting point, the number of simultaneous parameters is limited by the availability of 
fluorophores with appropriate characteristics.  In general, these fluorophores should be 
biologically inert (unable to bind to cellular elements or affect cells), have high cell-associated 
fluorescence intensities, exhibit little spectral overlap with one another, and should be easily 
conjugated to antibodies [47].   
The use of flow cytometry in biological and medical research, as well as in clinical 
medicine, underscores the versatility of this technology.  Most notably, cytometry is utilized for 
the characterization of hematologic malignancies based on immunophenotypic analysis of cells 
in the bloodstream.  However, cytometry also affords the opportunity to combine cell 
enumeration and immunophenotyping with measures of cell function, which provides clinicians 
and researchers with a richer set of information. 
 
2.2 CYTOMETRIC FUNCTIONAL ASSAYS 
 
A key component to identifying and understanding clinical disorders and host responses to 
stimuli is the ability to evaluate cellular function.  Compared to conventional biochemical 
functional assays, flow cytometry allows individual cells to be assessed without the need for a 
priori separation, which is especially important when dealing with complex cell populations such 
as peripheral blood mononuclear cells (PBMC).  Furthermore, the additional manipulation of 
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Figure 2. Relative kinetics of cell activation following stimulus [14].  
cells incurred by separation may alter a cell’s native function [12, 13].  Not only does flow 
cytometry allow one to examine individual cells without separation, but it also requires shorter 
protocol times, provides a larger dynamic range of data collection, dispenses of the need to 
radioactively label materials, and affords the ability to analyze rare subsets [48] and multiple 
epitopes within a single cell [49].   
There are a large number of functional assays suitable for flow cytometric analysis, 
including phagocytosis, gene expression, apoptosis, redox reactions, cytokine production, cell 
proliferation, cytotoxicity, and cell signaling [15, 50-55].  Although flow cytometry significantly 
decreases the protocol time compared to traditional methods, for many of these assays, 
incubation times may be anywhere from several hours up to several days.  Figure 2 illustrates the 
stages of T cell activation in response to a stimulus [14].   Early responses are defined as those  
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that occur within seconds to minutes, intermediate responses occur within several hours, and late 
events after several days.  Assays developed as clinical diagnostics should be designed to be 
robust and rapid to quickly screen patient samples, thus reducing the interval that the cells are 
manipulated (i.e. culture, incubation, storage), which could introduce artifactual responses.   Of 
the functional assays listed, the early events in cell signaling, such as phosphorylation and 
calcium influx, occur most rapidly.  However, of these, only phosphorylation yields specific 
information concerning distinct signaling pathways within the cell.  Accordingly, we plan to 
focus our studies on the upstream phosphorylation of proteins belonging to important signaling 
networks that control immune regulation.  
         
 
2.3 ASSAYS TO ASSESS PROTEIN PHOSPHORYLATION 
 
Since the transcriptome, reflecting gene expression, does not always correlate directly with the 
amount of protein expressed [56, 57] and does not account for post-translational modification 
including phosphorylation, which is integral to protein function, it is important to directly 
analyze proteins.  Proteins drive much of cell biology, such as structural aspects of cellular 
integrity, signaling molecules, entry and exit from the cell cycle, mediating many of these 
functions especially when phosphorylated.  As Philip Cohen mused, “the reversible 
phosphorylation of proteins regulates nearly every aspect of cell life [58].”  As many as 30% of 
all human proteins are capable of being phosphorylated.  Taken altogether, it is clear that protein 
phosphorylation is a major regulatory component necessary for full understanding of cellular 
function.  
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Indeed, there are many approaches available to analyze phosphorylated proteins within 
cells.  As with every technique, each of these brings its own advantages and disadvantages to the 
table, depending on the experimental objectives.  A description and comparison of currently 
employed phospho-protein detection methods from conventional biochemical assays, such as 
Western blotting, to more recent advancements: protein microarrays, flow cytometry, and 
imaging cytometry, will shed light on the relative merits of each system.  One common element 
connecting these methods is the requisite use of antibodies with specificity for phosphorylated 
proteins. 
 
2.3.1 Phosphorylation state-specific antibodies (PSSAs) 
 
The first phosphorylation state-specific antibodies (PSSAs), both monoclonal and polyclonal, 
were developed in the 1980s against phosphotyrosine and to a lesser degree phosphothreonine.  
Unfortunately, these antibodies did not have specificity for any single protein; rather they 
provided information regarding pan-proteome phosphorylation.  PSSA technology advanced in 
the early1990s when monoclonal and polyclonal sequence-specific PSSAs were developed [59].  
These antibodies were generated by injecting animals with enzymatically phosphorylated 
peptides and screening the resultant hybridomas for phospho-specificity (for monoclonals) or 
affinity-purifying phospho-specific antibodies from the sera (for polyclonals).  Today, more 
efficient chemical techniques that do not rely on enzymes are available to phosphorylate peptides 
used to generate PSSAs.     
Once a sequence-specific PSSA has been produced, it must be validated for its 
specificity.  Typically, this is first accomplished by Western blotting.  In a Western blot, the 
PSSA should demonstrate a single band at the appropriate molecular weight, unless other cross-
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reactive proteins, degradation productes, splice variants, or allelic variants share a linear 
confirmation similar to the primary amino acid sequence of the peptide used to generate the 
PSSA.  Secondarily, the PSSA should reveal phosphorylation of cultured cells in response to 
known activating stimuli.  Another method of probing specificity is to preincubate the PSSA 
with an excess of the immunizing antigen to determine if it abrogates its immunoreactivity.  
Critical confirmation could also use strategies where one substitutes the amino acid at the 
phosphorylation site of the individual target protein within a cell of interest thereby disabling 
phosphorylation and proving specificity of the PSSA.  Since their initial description, PSSAs have 
found their way into many applications useful for detecting changes in phospho-protein 
expression.    
 
2.3.2 Western blotting 
 
One traditional, yet powerful, method of detecting specific proteins within complex mixtures, 
such as cell lysates, is referred to as immunoblotting or Western blotting.  Developed in 1979 by 
Harry Towbin, it was originally designed to detect ribosomal proteins [60], but has been applied 
to an enormous number of proteins including post-translational modifications such as 
phosphorylation.  In short, the method consists of four basic steps: separating proteins by size via 
gel electrophoresis, transferring resolved proteins to a membrane, incubating the membrane with 
antibodies to a specific protein, and detecting the bound antibody.  A generic Western blot 
procedure, utilizing a colorimetric method of detection, is illustrated in Figure 3 [61].              
After an initial period of culture, during which cells may be treated with an agent of 
interest, the cells are lysed, typically in the presence of protease inhibitors to prevent protein 
degradation.  Additionally, when detecting phosphorylated proteins, it is important to include  
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Figure 3. Generic Western blotting procedure utilizing a colorimetric detection method [61]. 
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phosphatase inhibitors during this step.  To quantify differences in protein levels between 
different treatment groups, protein concentrations should be approximately equal.  This can be 
achieved by performing an assay to measure the total amount of protein present in cell lysates, 
such as the colorimetric bicinchoninic acid (BCA) assay, then performing appropriate dilutions.   
If this step is ignored, differences may still be roughly quantified by normalizing the apparent 
amount of protein to another protein with relatively constant levels of expression, such as β-
actin.   
Separation of proteins from the complex mixture in cell lysates is accomplished by gel 
electrophoresis, which exploits differences in protein molecular weight.  In short, a voltage is 
applied across a gel, typically polyacrylamide, which drives smaller proteins to migrate through 
the gel at a faster rate than larger proteins.  Molecular weights are determined by running a 
“ladder” through the gel to create markers of known molecular weight.  Since proteins exist in 
various conformations, i.e. some proteins with higher molecular weight may be more compact, 
thus able to migrate through the gel faster, it is necessary to denature them and reduce any 
disulfide bonds prior to electrophoresis.  In many cases, boiling the proteins in the presence of β-
mercaptoethanol is sufficient to reduce disulfide bonds and denature proteins.  Additionally, the 
proteins’ native charges must be masked by incorporating sodium dodecyl sulfate (SDS), which 
adds negative charge and also contributes to protein denaturation.   
Once the voltage has been applied and the proteins have been separated, the proteins may 
be transferred to a membrane.  In this step, the gel is placed on a membrane capable of binding 
any protein, such as nitrocellulose or polyvinylidene fluoride (PVDF), and another voltage is 
applied through a buffer to transfer all of the separated proteins from the gel to the membrane, 
creating a replica pattern.  Before antibodies can be used to detect proteins of interest, the 
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membrane must be blocked to prevent non-specific antibody binding.  Often, non-fat dry milk is 
used for this purpose, however BSA is the blocking agent of choice for phospho-protein 
detection when using pan-phosphotyrosine, -serine, or –threonine antibodies, as milk contains 
many phosphorylated proteins.  After blocking, a primary antibody targeted against a protein of 
interest, such as a PSSA, should be incubated with the membrane.  After several washes with 
mild detergent to remove non-specific binding, a secondary antibody containing a detection 
method should be incubated with the membrane.  Protein visualization can be accomplished by 
colorimetric, fluorescent, chemiluminescent , or radioactive detection [62].  Of these, the highest 
sensitivity without using radioactivity is achieved with chemiluminescence, where luminol is 
oxidized to produce light, which is detected on x-ray film.  With the noted minor procedural 
modifications, Western blotting is applicable for the detection of phosphorylated proteins.  This 
is especially useful when a relatively homogenous cellular population is used.    
  
2.3.3 Protein microarrays 
 
Another, more recently developed technique, capable of analyzing post-translational 
modifications of proteins, like phosphorylation, is the protein microarray, which was built upon 
the success of earlier gene arrays.  In principle, microarrays are miniaturized bait-and-capture 
assays.  Several different formats have been developed over the years relying on different bait 
molecules, such as aptamers, antibodies, cell lysates, phage or recombinant protein/peptide, 
nucleic acids, or tissue, immobilized into hundreds of spots on a substrate [63].  In most cases, 
the capture component is a complex biological mixture of proteins, such as cell lysates and 
serum.  In order to visualize proteins bound to the array, various detection strategies have been 
devised.  In general, they are classified as label-free and labeled probe.  Label-free detection 
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methods include mass spectrometry, surface plasmon resonance, and atomic force microscopy, 
while labeled probe methods, which differ based on the immobilized bait molecule, incorporate 
fluorescent, chemiluminescent, chromogenic, or radioactive detection methods[63].  Due to their 
high sensitivity and resolution, ease of use and clean up, fluorescent strategies have become the 
method of choice for microarray analysis [64].  In forward phase or antibody array formats, 
many antibodies against specific proteins are spotted; then a mixture of directly labeled proteins 
from lysates or serum is applied to the array.  Spots containing proteins of interest will produce a 
signal proportional to the amount of protein bound to the array.  Similarly, phosphorylated 
proteins may be analyzed by spotting various PSSAs onto the array.  Additionally, sandwich 
assays, analogous to ELISA, have been applied to microarrays, where proteins are captured by 
immobilized antibodies and subsequently detected by directly labeled antibodies.  In a direct 
capture format, also referred to as reverse phase protein microarrays, complex mixtures of 
proteins, such as lysates from various biopsies or cell cultures, are immobilized onto an array to 
be detected by directly labeled antibodies.  In the same way, phospho-proteins may be analyzed 
by applying labeled PSSAs.  Using forward phase, one can analyze a large number of protein 
targets within a single specimen simultaneously.  Conversely, with reverse phase, one analyzes a 
single protein target across many samples.   
Because of the high-throughput nature of this technique, protein microarrays have proven 
useful for detecting differences in protein expression levels between healthy individuals and 
those with various disorders [16, 65].  For example, protein expression levels in the clinical 
disorder, spinal muscular atrophy, highlights the importance of analyzing phosphorylation 
events, as it provides evidence that the amount of a protein does not necessarily correlate with 
the amount of phosphorylated protein.  Specifically, total JNK1 levels were lower in the setting 
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of apparent disease, whereas phospho-JNK1 levels were higher [16].  Thus, protein microarrays 
are a promising technology that can be easily adapted to study the phospho-proteome and 
provide insights into disease mechanisms. 
 
2.3.4 Flow cytometric method 
 
With the advent of flow cytometry, a powerful new method of analyzing multiple parameters 
within single cells became available.  The premise on which the technology is based is the ability 
to identify cells due to light scatter properties, while cellular elements are detected by measuring 
fluorescence from fluorophore-conjugated antibodies directed against components of interest.  
These may be detected on the cell surface, which is a relatively straightforward labeling 
procedure, or within the cell, as is the case for phosphorylated proteins.  In the latter case, the 
method of staining is more complex and requires protocol optimization for individual targets.   
In general, the flow cytometric detection of phosphorylated proteins involves stimulating 
cells, followed by fixing, permeabilizing, and application of fluorophore-conjugated PSSAs.  
When developing a protocol based on these steps, it is important to keep in mind the following 
technical considerations: antigen accessibility, cellular localization, stability of the phospho-
epitope, antibody and fluorophore selection, and maintenance of surface staining and scatter 
properties [18].  After cells are stimulated to induce phosphorylation of a protein of interest, they 
should be fixed to maintain the stability of the phospho-epitope.  The concentration and choice of 
fixative, as well as time of fixation, are important, as these will affect antigen accessibility, 
stability of the phospho-epitope, autofluorescence, and scatter properties.  If a fixative is too 
strong, concentrated, or applied too long, it may fix proteins to such a degree that phospho-
epitopes are no longer available to bind an individual antibody.  Conversely, if the fixative is 
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insufficient, the stability of the phospho-epitope may be in jeopardy, as phosphatases may still be 
active.  Some fixatives, such as glutaraldehyde, increase the autofluorescence of individual cells,  
including monocytes, which can mask the signal obtained from some fluorophores.  
Additionally, some fixatives may alter scatter properties, which may be troublesome when 
defining specific cells within complex mixtures.   
Once a fixation method has been optimized, a permeabilization strategy must be 
developed to allow PSSAs access to the interior of the cell.  As with fixation, permeabilization 
affects phospho-eptiope detection in a number of ways.  Antigen accessibility is a major issue, as 
many phospho-epitopes are buried by protein-protein interactions, such as within SH2 domains.  
Furthermore, most PSSAs are generated to a linearized phospho-peptide, which requires 
denaturing the native protein structure.  Therefore, permeabilizers, such as alcohols, that not only 
solubilize components of the cell membrane, but also induce denaturation, are often required.  
Additionally, cellular localization of the protein of interest, whether it is nuclear or cytoplasmic, 
must be considered when choosing a permeabilization method.  If one is interested in combining 
surface staining with phospho-protein detection to phenotype cells, it is important to use a 
permeabilizer that will not be detrimental to plasma membrane-bound epitopes.  Like fixation, 
different permeabilization agents also have the ability to alter cell scatter properties.  Before cells 
are labeled with PSSAs, it is important to block any potential non-specific binding by incubating 
the cells with an ‘Fc-blocking agent’, such as nonimmune, normal polyclonal IgG of the same 
species as the specific PSSA [66].   
In the next essential step, the phosphorylated protein is labeled with a fluorophore-
conjugated PSSA.  As already noted, the PSSA must be validated for its specificity to only the 
phosphorylated form of the protein, but applying it to fixed and permeabilized cells requires 
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further validation, as certain clones of monoclonal antibodies provide more intense and specific 
staining of intracellular antigens [67].  Another point of consideration is the choice of 
fluorophore attached to the PSSA; a larger one, such as APC or PE, may impede the antibodies 
ability to travel freely within the cell.  Furthermore, since phospho-proteins are normally 
expressed at low levels, it is important to choose a fluorophore that is “bright.”  To limit the 
amount of non-specific labeling, the antibody should be titrated and incubated with the cells for 
an appropriate length of time.   
In any flow cytometric experiment, it is important to include several types of controls, 
including a positive control with a stimulus known to induce protein phosphorylation, detected 
with a validated PSSA.  Additionally, a negative control should be employed.  Many groups have 
utilized isotype controls, which are nominally non-specific antibodies of the same type as the 
PSSA.  However, the use of isotype controls is generally of little value because each antibody 
and conjugate has different characteristics in terms of “stickiness” and background staining 
characteristics [47].  Likewise, if there were a discrepancy between the FTP ratios of the isotype 
and PSSA (the number of fluorophores conjugated per antibody), it would be difficult to draw 
firm conclusions.  As a more appropriate control, it is recommended to treat stimulated and 
unstimulated cells with the same PSSA.  Although this will not offer a measure of basal 
phosphorylation, it will provide a means of detecting specific phosphorylation following 
stimulation.  If cells are simultaneously stained for multiple targets, surface proteins and 
phospho-epitopes or multiple phospho-epitopes, it may be necessary to include compensation 
controls.  This is necessary when the fluorophores employed have a sufficient degree of spectral  
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overlap, which will cause a fluorophore to contribute signal to several individual detectors.  To 
remedy this, compensation is applied, which mathematically limits the contribution of 
fluorophores in detectors to which they are not assigned.     
Several groups have successfully analyzed phosphorylated proteins, such as pSTAT1, 
pSTAT4, pSTAT5, pSTAT6 and pERK via flow cytometry and obtained qualitatively similar 
results with Western blotting [15, 19, 20, 68, 69]. However, most of these studies were 
performed on homogeneous cell populations or did not combine cell surface staining to subset  
populations from complex mixtures.  In spite of these caveats, flow cytometry is indeed a 
promising technique for evaluating protein phosphorylation with several advantages over other 
available technologies. 
 
2.3.5 Imaging cytometry  
 
Like flow cytometry, imaging cytometry has been utilized for a large number of biological 
applications including cell cycle analysis, cell signaling (mainly translocation from the 
cytoplasm to the nucleus), cell-cell interactions, cell motility, receptor internalization, and 
assessing cell death pathways.  Imaging cytometry combines molecular, morphologic, and 
phenotypic information at the single-cell level, providing substantial detail [70]. The inclusion of 
morphological parameters is one of the main differentiating aspects from flow cytometry.  At 
present, there are a variety of imaging cytometers commercially available, each employing 
similar principles, but individual methods of fluorophore excitation and detection.  Most of the 
previously discussed technical considerations and sample preparation techniques associated with 
flow cytometry are also applicable to imaging cytometry. 
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 In general, imaging cytometry integrates fluorescent cell-based assays, automated high-
resolution microscopy, image processing algorithms, and informatics software used to archive 
and organize many images and quantitative results [71].  By obtaining images of intact cells and 
applying image processing algorithms, this technology affords the ability to perform spatio-
temporal measurements of fluorescence within various cellular compartments [72].  Once cells 
are prepared in culture plates and stained with fluorescent dyes or fluorescent-labeled antibodies, 
they must be excited to detect the components of interest.  Imaging cytometers employ a number 
of illumination sources including lasers, arc lamps, and light-emitting diodes (LEDs).  
Furthermore, various microscopy systems are utilized such as confocal, multiphoton confocal, 
digital, and conventional inverted fluorescence microscopy [73].  Additionally, photomultiplier 
tubes (PMTs), such as those used in flow cytometers, and CCD cameras have found use in 
imaging cytometers to detect emitted photons.  To enable measurement of multiple parameters, 
these systems typically have multiple band pass emission and excitation filters.  Overall, the 
laser-scanning-PMT imaging cytometers are more sensitive than the arc lamp-CCD camera 
systems, but are considerably more expensive.  Additionally, these laser-PMT systems are 
slower during image acquisition than less sensitive imaging cytometers.  However, both of these 
are slower at acquiring events than conventional flow cytometers [73].  Most imaging cytometers 
are completely or semi-automated, which includes automatic measurement of exposure times, 
autofocusing, and automatic plate scanning.  Because of this automation and the ability to 
multiplex, they are widely used in high-throughput screening strategies employed in drug 
screening programs.   
Another common feature of imaging cytometers is the use of image processing 
algorithms to indentify distinct cellular compartments.  To accomplish this, a particular region of 
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the cell or organelle, usually the nucleus, is labeled with a fluorescent marker from which a 
primary object is created in the software, as shown in Figure 4 [71].  This primary object is used 
to identify individual cells and subcellular regions.  Typically, the primary faux object created is 
a circle to identify the nucleus, which is eroded slightly and dilated outward as a ring within the 
boundaries of the cell to identify a region as the cytoplasm.  Within each of these regions, 
aggregates of higher pixel intensity are also capable of being identified by the algorithm.  This 
particular algorithm demonstrated is an application called “compartmental analysis” designed by  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic illustrating image processing algorithms used by imaging cytometry 
to define cellular localization [71].  
 22
Cellomics, Inc.  Fluorescence intensities can be measured in these defined areas as well as 
intensity ratios, intensity differences, spot numbers, and spot areas.  Obviously, morphological 
parameters, such as cell size, nuclear area and shape are also included in the measurements [71].             
With regards to cell signaling, cells may be stimulated, fixed, and permeabilized, keeping 
in mind the same considerations outlined for flow cytometry, and then labeled with fluorophore-
conjugated antibodies towards specific intracellular proteins of interest, including 
phosphorylated proteins to identify activated signaling pathways.  In this manner, it is possible to 
pinpoint the cellular localization of phosphorylated proteins, as images of the cells are acquired.  
Accordingly, the use of PSSAs is permitted, however they are not required to detect activation of 
signaling pathways.  Many signaling proteins, upon phosphorylation, form dimers that 
translocate to the nucleus to regulate gene transcription.  As a result, it is possible to label 
proteins with antibodies toward unphosphorylated epitopes since imaging cytometry provides the 
capability of measuring nuclear and cytoplasmic fluorescence intensities separately.  
Additionally, this compartmental analysis gives a sense for the amount of protein that is 
activated.  As a result of its ability to measure nuclear translocation events in single cells, 
imaging cytometry has been utilized to study a number of signaling pathways including NFκB 
[72, 74], p38 MAPK [72], and ERK [71].  Because of the ability to multiplex and obtain images 
of intact cells, this technology is also capable of analyzing heterogeneous cell populations and 
cell-cell interactions.  Individual cell lineages and subpopulations are readily identifiable by 
including fluorophore-conjugated antibodies towards cell-specific proteins.  Due to its high-
throughput nature and unique advantages, such as morphological assessment, and compartmental 
analysis, automated imaging cytometry is a powerful technique for scientists studying cellular 
function. 
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2.3.6 Comparison of phospho-epitope detection methods 
 
Although each of the technologies discussed possesses the ability to measure phosphorylated 
proteins, there are advantages and disadvantages associated with each.  The objectives of an 
experiment, for instance studying rare cells, heterogeneous populations or localization of 
components within cells, will determine which technique is most appropriate.  A direct 
comparison of the capabilities and limitations of these methods will help to elucidate their value.   
Compared to the other methods discussed, the primary advantage of flow cytometry is the 
ability to measure events in single cells, as opposed to bulk analysis methods, where it is rivaled 
only by microscopy and imaging cytometry.  Unlike microscopy, flow cytometry is not limited 
by the number of cells that can be analyzed in a short period of time.  The problem with 
microscopy is overcome in automated imaging cytometry, but these systems still acquire events 
slower than conventional flow cytometers, especially those capable of automatically acquiring 
96-well plate formats for sampling individual cell populations, such as the BD FACSArray.  It 
should also be noted, that imaging cytometry is best suited for adherent or semi-adherent cells.  
When cells are in suspension, rather than spread-out on a surface, it is much more difficult to 
create a region for the cytoplasm within the image processing software because the cell/nucleus 
diameter ratio is markedly lower.  Another disadvantage with imaging cytometry is the 
requirement of dealing with huge data files due to the large number of images acquired.   
Whereas flow and imaging cytometry measure events on a cell-by-cell basis, bulk 
analysis methods obtain a signal that is an average for an entire population of cells.  Bulk 
analysis methods would be unable to distinguish heterogeneity in responsiveness within a 
population, such as bimodal cell populations and all-or-none responses.  Western blotting and 
protein microarrays necessitate the use of homogeneous cell populations, whereas cytometry is 
 24
suitable for complex mixtures of cells due to the ability to immunophenotype and distinguish 
cells based on light scatter.  Imaging cytometers are only capable of providing light scatter 
information if a laser is used as the illumination source [75].  To study individual cell types from 
complex mixtures, such as PBMC, via non-cytometric based techniques, requires cell sorting or 
magnetic separation, which is time consuming and may introduce artifacts.  Another result of 
cytometry’s ability to analyze many cells on a single cell basis is rare event analysis, which is not 
feasible with the other methods discussed.  Cytometry is rich in statistical information because so 
many cells are analyzed individually within each experiment.  If the amount of sample is 
limiting, cytometry also offers an advantage because it requires fewer cells for analysis than 
Western blotting or protein microarrays.  Because flow cytometry affords the ability to stain 
multiple parameters simultaneously (currently up to 19), this also decreases the amount of 
sample needed for an experiment.  Imaging cytometers currently do not have the ability to 
measure as many parameters simultaneously.  At the same time, many more parameters, limited 
only by the number of available PSSAs spotted on a chip, can be analyzed by protein 
microarrays, whereas only one protein may be detected at a time on a Western blot.   
All of the advantages aside, flow cytometry does have limitations compared to other 
technologies.  Western blotting offers some unique advantages not attainable by flow cytometry 
or protein microarrays, such as determination of protein size, which can be used to verify proper 
labeling.  If cells are fractionated into nuclear and cytoplasmic components, microarrays and 
Western blotting can be used to determine cellular localization of proteins.  Even without 
fractionation, imaging cytometers are capable of measuring the localization of cellular 
components within intact cells.  With regards to sensitivity, the signal-to-noise ratio is typically 
higher with microarrays and Western blots because there is no noise contribution of 
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autofluorescent cells or problems with antigen accessibility, as with fixed and permeabilized 
cells.  Furthermore, as a result of enzymatic amplification, the signal obtained by Western 
blotting can be magnified.  Proteins with very low expression levels may be below the limits of 
detection by cytometry.  By design, Western blotting incorporates denaturing conditions, which 
exposes hidden phospho-epitopes. If this is not addressed in microarray or cytometry 
experiments, it is expected that one would obtain false negatives, as the PSSAs generated against 
linearized peptides will not be able to recognize phospho-epitopes in a protein’s native state.  
Table 1 summarizes some of the primary differences between each of the methods described.  No 
one technology should be considered the “best” without evaluating each of them contextually, 
keeping in mind the desired experimental objectives.  Because the aim of this study is to analyze 
early signaling events regulating immune function in peripheral blood mononuclear cells 
(PBMC), which are non-adherent cells, we have chosen to develop a flow cytometric-based 
method, which allowed us to study individual cells within this complex population. 
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 Western Blot Protein 
Microarray  
Flow Cytometry Imaging 
Cytometry 
Bulk or Single 
Cell Analysis 
Bulk Bulk Single cell Single cell 
Suitable 
Sample Type 
Homogeneous Homogeneous Heterogeneous Heterogeneous 
Ability to 
Study Rare 
Events 
No No Yes Yes 
Sample Size 
Needed 
Large (~106) Large (~106) Small (~105) Small (~104) 
Multiple 
Parameters 
No  Yes Yes  Yes 
Size 
Determination 
Yes No No No 
Intracellular 
Localization 
Determination 
Yes (if cells are 
fractionated) 
Yes (if cells are 
fractionated) 
No Yes 
Signal-to-
Noise Ratio 
No 
autofluorescence 
or antigen 
accessibility 
issues 
No 
autofluorescence 
or antigen 
accessibility 
issues 
Decreased by 
autofluorescence 
and antigen 
accessibilty 
Decreased by 
autofluorescence 
and antigen 
accessibility 
Table 1. Comparison of phospho-epitope detection strategies. 
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2.4 IMPORTANT PHOSPHO-SIGNALING PATHWAYS 
 
Cells often respond to environmental stimuli, such as factors released from cells, damage, and 
stress conditions, via rapid and sequential protein phosphorylation.  Depending on the cell type, 
stimulus, and context in which it is presented, phosphorylation events are triggered through 
distinct pathways, two major ones being the JAK/STAT and MAP kinase signaling pathways.  
The JAK/STAT pathway is important in regulating host defense, cell growth, development, and 
apoptosis.  Similarly, the MAP kinase signaling pathway plays a major role in regulating cell 
cycle progression, apoptosis, cytokine production, and cell differentiation in response to stress, 
inflammation, and other stimuli.  Due to their many important roles in controlling various aspects 
of cell life, it is critical to understand how these pathways normally function and how their 
dysregulation may contribute to abnormalities in immunity and cell growth and death.  
 
2.4.1 The JAK/STAT pathway 
 
Originally discovered by James E. Darnell Jr.’s group in 1992, STATs (signal transducers and 
activators of transcription) are a family of latent proteins that are activated via tyrosine 
phosphorylation, leading to nuclear translocation and regulation of gene expression.  There are 
seven identified STAT family members: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, 
and STAT6, ranging in length from 750 to 850 amino acids [26].  STATs share a number of 
functional domains, including the N-terminal domain, followed by a coiled-coil domain, a DNA-
binding domain connected by a linker to an SH2 domain, and a transactivation domain at the C-
terminus [76].  In general, extracellular proteins, mainly cytokines and growth hormones, 
activate STATs after they bind to their cognate receptors.  When a ligand binds to its receptor it 
induces receptor dimerization, as is the case for growth hormone or erythropoietin, or they form 
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heteromultimers, as is true for many interleukins and interferons [77].  Following this step, 
protein kinases called Janus kinases (JAKs) that are noncovalently associated with receptors 
transphosphorylate each other and the receptors to which they are bound.  Phosphorylation of the 
receptor provides a docking site for STAT proteins via their Src-homology-2 (SH2) domain.  
Upon binding to the receptor, STATs are phosphorylated on a single tyrosine residue between 
their SH2 and transactivation domains by JAKs.  This step leads to the formation of STAT 
homo- or heterodimers through reciprocal SH2/phosphotyrosine interactions.  All STAT family 
members can form homodimers, while STAT1/STAT3, STAT5a/STAT5b, and 
STAT1/STAT2/IRF9 can form heterodimers and –trimers, respectively.  Monomeric 
phosphorylated STATs have not been identified.  Once the dimers are formed, STATs may enter 
the nucleus through interactions with importins and their nuclear localization sequence (NLS) to 
regulate transcription of a variety of genes depending on the nature of the dimer and its 
interaction with other nuclear proteins.  This basic scheme of STAT activation is illustrated in 
Figure 5 [26].   
Within the nucleus, STAT dimers bind directly to consensus sites within promoter or 
enhancer regions of genes.  Gamma activated sequences (GAS) or interferon sensitive response 
elements (ISRE) are primary examples for STAT1 and STAT2.  Because many of these regions 
are roughly 20 base pairs apart, the STAT dimers often form tetramers through interactions 
between their N-termini [26].   Additionally, STAT dimers may regulate transcription without 
direct binding by interacting with other proteins in enhanceosomes through TAD  
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Figure 5. Schematic illustrating a general and simplified pathway of STAT activation [26]. 
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interactions.  In order to be exported from the nucleus, it is important for STAT proteins to 
become dephosphorylated by nuclear phosphatases [26].  The total activation-inactivation cycle 
time for a STAT protein is estimated to be approximately 20 minutes. 
 
2.4.1.1 Alternative methods of JAK/STAT activation  In contrast to the canonical pathway, in 
which STATs are tyrosine phosphorylated by JAKs, alternative methods of activation exist.  For  
example, the receptors for many growth factors acting on the JAK/STAT pathway contain 
intrinsic tyrosine kinase activity, negating the requirement for JAK involvement [22].  It is also 
proposed that seven transmembrane domains can activate STATs after they bind peptide, 
presumably through associations with non-receptor tyrosine kinases [26].  Although not 
necessary for nuclear translocation, STATs are serine phosphorylated in their C-terminal domain 
in response to bacterial infection, which increases transcriptional potency.  This also provides an 
opportunity for cross-talk between individual pathways, as MAP kinase is implicated in serine 
phosphorylation of STATs [77].  With regards to the status of unphosphorylated STAT proteins, 
very little is known.  Recently, nonphosphorylated STATs were shown not to exist as monomers.  
For example, in human Hep3B cells, STAT3 associates as dimers or higher order statosome 
complexes, often associated with clathrin, implicating a role of endocytosis in STAT signaling 
[78].  Another group observed nonphosphorylated STAT dimers with two unique crystal 
structures.  In one structure, the dimer is formed by interactions between coiled-coil (CC) and 
DNA binding domains (DBD) in an antiparallel manner.  In the other, the STATs are parallel 
with their N-termini lodged between them.  Mutations to the N-termini, DBD, and CC did not 
affect tyrosine phosphorylation, but increased resistance to dephosphorylation [79].  
Additionally, in MCF-7 breast cancer lines and HeLa cervical cancer lines, nonphosphorylated 
and tyrosine mutated STAT3 were still capable of forming dimers.  However, mutation of a 
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single lysine residue, which is acetylated, prevented the formation of STAT3 homodimers [80].  
The associations of nonphosphorylated STATs are likely to be unique within distinct cell types 
and additional work is required to understand their importance. 
           
2.4.1.2 Negative regulators of JAK/STAT signaling  Like most physiologic processes, the 
JAK/STAT pathway is homeostatically regulated by inhibitory mechanisms.  There are three 
major families of proteins that negatively affect STAT phosphorylation: protein tyrosine 
phosphatases (PTPs), suppressors of cytokine signaling (SOCS), and protein inhibitors of 
activated STATs (PIAS) [77].  Of these, only the SOCS family of proteins is inducible following 
STAT activation; the remainder are constitutively expressed [81].  PTPs are perhaps the simplest 
class of inhibitory molecules.  Some members of this family (SHP1, SHP2, CD45, PTP1B) exert 
their effects by dephosphorylating JAKs or the phosphorylated docking site on the associated 
receptor. Additionally, some PTPs have the ability to dephosphorylate STATs on both tyrosine 
and serine residues within the cytoplasm (SHP2, PTP1B, TCPTP) and nucleus (TCPTP, SHP2) 
[76].  In a classical negative feedback loop, the SOCS family of proteins of which there are eight 
members (CIS and SOCS1-7) are upregulated in cells following cytokine stimulation [76].  
Individual members of the family mediate inhibiton, binding to phosphorylated JAKs to prevent 
their activity or to phosphorylated receptors to compete for STAT docking sites.  Additionally, 
SOCS proteins can regulate ubiquitin-mediated proteosomal degradation of its targets as another 
mechanism of inhibition through interactions with ubiquitin ligases [81].  Because these proteins 
are inducible, they do not affect initiation or strength of STAT activation, only the kinetics of 
signal termination.  There is new evidence to suggest that SOCS family members display cell-
specific selectivity in their regulatory actions [82].  Members of the family of negative 
regulators, PIAS, consisting of four members (PIAS1, PIAS3, PIASX, and PIASY), bind to 
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activated STAT dimers and prevent them from binding DNA [77].  However, PIAS members 
have been shown to inhibit STAT activity without affecting their DNA binding capacity, 
possibly through interaction with histone deacetylases (HDACs) [76].  PIAS also sumolyates 
STATs, which inhibits their activity in a way that is not fully understood [81].  In normal cells, 
these three main classes of negative regulators manage to regulate the JAK/STAT pathway.   
  
2.4.1.3 Gene ablation studies of JAK/STAT family members  Except for STAT3 which is 
embryonic lethal, most STAT proteins are not necessary for survival or development.  Their 
individual roles have been studied through gene deletions in mice.  The slower growth of cells 
induced by interferon is fully dependent on transcriptionally active STAT1.  This molecule 
mainly promotes apoptosis and growth arrest.  Deletion in mice increases susceptibility to viral 
infection and tumor formation [21].  To date, STAT2 has only been implicated in type I 
interferon signaling, promoting antiviral responses [25].  STAT3 is associated with dual and 
opposing roles.  In many instances, STAT3 activation induces cell proliferation and anti-
apoptosis, but in other cell types and contexts, it plays a role in promoting apoptosis and 
differentiation [21].  STAT3’s role in cancer has been explored heavily because its persistent 
activation via a mutant protein, where the phosphotyrosine/SH2 interactions are substituted for 
disulfide bonds, is sufficient for cellular transformation [25].  In other knockout studies, the 
absence of STAT4 and STAT6 leads to defects in response to cytokines that regulate polarization 
of naïve T cells into Th1 and Th2 groups, respectively, thus resulting in impaired cell-mediated 
and humoral immunity [83].  STAT5a and STAT5b, share 96% homology, but perform many 
non-overlapping functions.  For instance, mammary gland development is impaired in STAT5a  
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deficient mice, but not STAT5b.  T cells in STAT5a null mice exhibit decreased proliferative 
capacity and IL-2Rα expression, while STAT5b deficient T cells have a more marked abrogation 
of proliferation and lower NK cell counts with diminished cytolytic activity [25].   
In summary, the STAT family of transcription factors is responsible for controlling a host 
of important cellular functions, not limited to immunity alone.  In all, over 40 polypeptides are 
known to activate the JAK/STAT pathway [21], which highlights its critical role in controlling 
many cellular functions.  Because this family of proteins is so important in regulating cell 
proliferation, apoptosis, and immunity, it should not be surprising that its dysregulation is 
associated with many types of cancer.  The involvement of disordered STAT signaling in several 
important diseases emphasizes the urgency to understand this pathway in normality and clinical 
disorders. 
 
2.4.2 The MAP kinase pathway 
 
The mitogen-activated protein (MAP) kinase pathway is responsible for controlling cellular 
reactions to mitogenic and stress stimuli.  Within the MAP kinase pathway are four main 
modules that have specificity for particular stimuli; these are extracellular signal-related kinases 
(ERK1/2), Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38α/β/γ/δ), and ERK5.  
Essentially, each module is regulated by three sequential protein phosphorylations, whereby an 
activated MAP kinase kinase kinase (MAPKKK) phosphorylates a MAP kinase kinase 
(MAPKK), which in turn phosphorylates a MAP kinase (MAPK) [23].  The distal activated 
MAPK phosphorylates additional specific effector kinases called MAPK activated 
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Figure 6. A schematic illustrating major modules of the MAP kinase signaling 
pathway [84]. 
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protein kinases (MKs) or translocates to the nucleus to regulate transcription directly.  A basic 
schematic for these signaling cascades is illustrated in Figure 6 [84].  Built into each of these 
modules is increasing complexity, as scaffolding proteins are believed to participate in signaling 
by spatially localizing proteins or even directly activating them [85].  Overall, the MAP kinase 
signaling pathway is an extremely complex cascade of phosphorylated proteins that arms cells 
with the ability to respond to environmental stresses and growth cues, making it critical for cell 
proliferation and survival. 
  
2.4.2.1 Mechanisms of p38 activation  Activation of p38 proteins is a major pathway by which 
cells respond to proinflammatory cytokines and environmental stress.  First identified in 1994 as 
a MAPK targeted by endotoxin and hyperosmolarity, p38 exists as four different isoforms: α, β, 
γ, and δ.  Of these p38α is the most extensively studied.  In mice, p38α and β are expressed 
ubiquitously, while p38γ is mainly associated with muscle and p38δ is predominantly localized 
to kidney and lung [86].  After cells are stimulated by proinflammatory cytokines or stress, such 
as heat/osmotic shock, oxidation, or UV irradiation, members of the Rho family of small 
GTPases, including cdc42 and Rac are activated [87].  Because many MAPKKKs contain a 
potential GTPase-binding motif (CRIB), these may lead to their direct activation.  Several 
MAPKKKs, such as MEKKs 1-4, MLK2 and 3, DLK, ASK1, Tpl2, and Tak1, have been 
implicated in p38 signaling [84], which probably depend on the particular stimulus and cell type 
at hand.  Further downstream in the p38 module, MAPKKKs activate MAPKK via 
phosphorylations.  Two MAPKKs with high specificity for p38 are MEK3 and MEK6; MEK6 
activating all p38 isoforms, while MEK3 is selective for α and β.  Another MAPKK, MEK4, is 
capable of phosphorylating p38, albeit less selectively, as it activates JNK as well [84].  Through 
these interactions with upstream kinases, p38 is phosphorylated on conserved tyrosine and 
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threonine residues within its kinase subdomain VIII.  Once p38 is activated, it is capable of 
phosphorylating transcription factor substrates including ATF2, Elk-1, CHOP, MEF2C, and 
SAP-1 or downstream effector kinases, such as Mnk1, Mnk2, PRAK, and MSK1 [88].  There is 
cross-talk between p38 and another major signaling pathway, NFκB.  As an activator of p38, 
sodium salicylate, inhibits NFkB [86].  Through these complex interactions with an array of 
transcription factors, kinases and other signaling pathways, p38 centrally controls gene 
expression in response to cell stress and inflammatory environments. 
   
2.4.2.2 Mechanisms of ERK1/2 activation  Another module of the MAPK signaling pathway, 
ERK1/2, is more responsive to mitogens, rather than stress and inflammation.  In the ERK 
signaling pathway, mitogens commonly activate a small GTPase known as Ras via receptor 
tyrosine kinases or G-protein-coupled receptors.  Membrane-associated Ras is activated by 
recruitment of SOS, a guanine nucleotide exchange factor, stimulating Ras to exchange GDP for 
GTP [84].  In turn, Ras activates Raf (A-Raf, B-Raf, and Raf-1), a serine-threonine kinase, which 
phosphorylates the MAPKKs, MEK1 and MEK2.  These kinases are the immediate upstream 
activators of ERK1 and ERK2, which share 83% homology in amino acid sequence [89].  Once 
activated by dual phosphorylations on conserved tyrosine and threonine residues in their 
activation loop, ERK1 and 2 translocate to the nucleus, presumably as dimers, to activate 
transcription factors responsible for controlling gene expression.  Additionally, activated ERK1/2 
phosphorylate numerous membrane proteins (CD120a, Syk), nuclear substrates (Elk-1, c-fos, c-
myc), cytoskeletal proteins (neurofilaments, paxillin), and other kinases [84].  Similarly to p38,  
ERK is also regulated by interactions with docking and scaffold proteins, which serve to control 
its cellular localization [90].  The ERK pathway is able to modulate the effects of growth factors 
and other mitogens through these coordinate and intricate interactions.  
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 2.4.2.3 Negative regulators of MAP kinase signaling  A set of proteins exist to inhibit 
activation of MAP kinase signaling.  Numerous phosphatases negatively regulate this pathway, 
including protein phosphatase 2C (PP2C), protein phosphatase 2A (PP2A), protein tyrosine 
phosphatases (PTPs), and dual specificity phosphatases (DSPs), which dephosphorylate both 
tyrosine and threonine residues [91].  Dephosphorylation of either the tyrosine or threonine 
residue within the MAP kinase activation loop is sufficient for enzymatic inactivation [92].  
Protein phosphatases 2C and 2A are two of four major serine/threonine phosphatases that exist in 
eukaryotes.  PP2A has been implicated in ERK inactivation through its ability to 
dephosphorylate threonine residues [92].  PP2C plays a role in dephosphorylating some of the 
upstream kinases of p38, MKK4 and MKK6, both in vitro and in vivo [87].  Additionally, three 
PTP gene family members, PTP-SL, STEP, and HePTP, are thought to play a role in inactivating 
ERK [92].  A subclass of PTPs that are referred to as DSPs are inducible depending on the 
specific stimulus and cell type upon which it acts, designating this as a classic negative feedback 
mechanism.  Evidence suggests that DSPs play a major role in regulating the activation of the 
MAP kinase signaling pathway, with each DSP displaying specificity for individual kinases.  For 
example, MAP kinase phophatase 3 (MKP3), a dual specificity phosphatase (DSP), specifically 
dephosphorylates ERK, but not JNK or p38.  On the other hand, MKP5 and M3/6 
dephosphorylate JNK and p38, but not ERK.  Some DSPs, such as MKP1 and MKP4, 
dephosphorylate all three major kinases [91]. By no means is this a complete picture of MAPK 
negative regulation, but it provides an overview of some of the major families of phosphatases 
involved.  By controlling the temporal patterns of MAPK activation, these proteins shape the 
effects of various stimuli and maintain the transient nature of this pathway in normal cells. 
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2.4.2.4 Roles of MAP kinase signaling in cellular function  Although the effects of MAP 
kinase signaling are both cell type and stimulus dependent, several generalizations have been 
made concerning its role in cell function.  Induced by proinflammatory cytokines, like IL-1 and 
TNFα, and cell stress, p38 activation is believed to modulate wide-ranging events including 
cytokine production, platelet aggregation, hepatocyte growth, cytoskeletal organization, 
apoptosis induction, and cell differentiation [93].  p38 plays an important role in regulating 
immune function in particular.  In mice, p38 activation blocks the differentiation of immature 
thymocytes, leading to immunodeficient mice.  Through studies with p38 inhibitors, p38 
activation was also found to be necessary for Th1 polarization of T cells, as well as IFNγ 
production from these cells [88].  On the other hand, p38 activation was not necessary for Th2 
polarization, whereas ERK activation was, mainly through regulation of IL-4 receptor function.  
It should be noted, however, that p38 may mediate opposing roles depending on the cell type, 
context, and p38 isoform activated [93].  Unlike p38, the ERK module is predominantly 
activated by growth factors and phorbol esters.  In response to these stimuli, ERK primarily 
serves to influence cell proliferation, differentiation, and survival [90].  ERK is an especially 
important protein in controlling cell growth, as its persistent activation due to mutations in Ras, 
an upstream activator, is often associated with increased proliferation of tumor cells [85].  In 
general, ERK activation is tied to cell survival and proliferation, while p38 activation is  
associated with pathways that ultimately result in apoptosis [23].  Because dysregulation of ERK 
and p38 activation, just as JAK/STAT proteins, leads to impairments in cell growth, it is crucial 
to study their involvement in disorders such as cancer. 
 
 
 39
2.5 ABERRANT PBMC SIGNALING IN THE SETTING OF CANCER 
 
Blood is routinely drawn in a clinical setting through minimally invasive means, and circulating 
white blood cells are akin to migrating biosensors, serving as suitable targets for analysis.  As 
their normal function is to act as sentinels and quickly respond to immune challenges and tissue 
damage, we chose to focus our analysis on signaling within PBMC.  Many studies, which will be 
briefly touched upon, suggest dysfunctional JAK/STAT and MAP kinase signaling within 
cancerous PBMC.  However, some studies also suggest that the presence of tumor affects the 
signaling and function of normal PBMC.  Since the JAK/STAT and MAP kinase pathways are 
extremely responsive to stress, inflammation, and cytokines, it is not surprising that an altered 
microenvironment caused by abnormal cytokine secretion from tumors, their surrounding 
stroma, or infiltrating immune effectors would induce abnormal signaling within PBMC 
circulating through these regions. 
  
2.5.1 Dysfunctional JAK/STAT and MAP kinase signaling in leukemic cells 
 
Inappropriate activation of JAK/STAT and MAP kinase signaling pathways is a common feature 
of many leukemias.  Overactivation of these pathways is associated with cellular transformation 
by oncoproteins that are results of genetic mutations, such as chromosomal translocations.   In 
other instances, persistent activation is attributed to autocrine and paracrine signaling via  
abnormally secreted cytokines.  These dysregulated pathways are believed to be causative agents 
in cancer progression through their effects on target genes responsible for cell proliferation and 
apoptosis. 
 An overview of signaling within various types of leukemia highlights the widespread 
dysregulation of JAK/STAT in the setting of cancer.  One type of leukemia, known as chronic 
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myelogenous leukemia (CML), results from chromosomal translocation, producing a 
constitutively active tyrosine kinase called BCR/ABL.  This chimeric oncogene possesses the 
ability to induce constitutive activation of the Ras-ERK2 and JAK/STAT pathways.  In 
particular, abnormal phosphorylation of STAT5 and to a lesser extent STAT1 and STAT3 has 
been observed in human CML cell lines and primary CML cells [30].  In these cells, JAKs were 
not activated, suggesting BCR/ABL induces STAT phosphorylation directly.  Another fusion 
protein called TEL-PDGFR, is responsible for causing a subgroup of chronic myelomonocytic 
leukemia (CMML).  In several CMML cell lines, TEL-PDGFR is capable of directly inducing 
constitutive activation of STAT1 and STAT5 without JAK involvement [94].  In primary cells of 
acute myelogenous leukemia (AML), which is characterized by maturation arrest followed by 
accumulation of undifferentiated myeloid cells in the bone marrow and peripheral blood, 
activated STAT1, 3, and 5 has been reported [29, 95].  An activating mutation in FLT3 tyrosine 
kinase is frequently associated with STAT phosphorylation in many AML patients.  
Additionally, primary T and B cells from acute lymphocytic leukemia (ALL) patients exhibit 
highly activated STAT5 and STAT1 to a lesser degree [94].  Another type of leukemia, called 
adult T cell leukemia (ATL), which is commonly induced by human T lymphotrophic virus I 
(HTLVI), is reported to contain constitutively phosphorylated STAT3 and STAT5 [29].   
In addition to the JAK/STAT pathway, dysregulation of the MAP kinase pathway is 
frequent in leukemic cells.  In fact, mutations leading to activated Ras occur in 30% of all 
cancers, including AML, and juvenile myelomonocytic leukemia [96].  Presumably, these 
mutations are responsible for constitutive activation of ERK1/2 and its upstream effectors 
MEK1/2 in primary human AML cells [97].  However, these Ras mutations do not always 
correlate with abnormal phosphorylation, suggesting that other mechanisms, such as paracrine 
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and autocrine factors, play a role.  Independent of Ras, hairy cell leukemic cells, which are 
intrinsically activated, mature clonal B cells, contain phosphorylated p38, JNK, and ERK.  
Though p38 and JNK are activated, they appear to play a role in inducing apoptosis, while ERK 
counteracts their effects by promoting hairy cell survival [31].  Additionally, ERK and p38, but 
not JNK, are constitutively phosphorylated in many other primary B cell neoplasms [98].  
Likewise, inappropriate activation of the ERK pathway is associated with NK cell leukemia [97].  
In summary, within hematological malignancies themselves, aberrant JAK/STAT and MAP 
kinase signaling is commonly observed, either as a result of genetic mutations or altered 
environments induced by malignant cells. 
   
2.5.2 Altered cytokine expression in tumor microenvironments  
 
Within the local environment of a tumor, there exists a complex interplay between tumor cells, 
activated stroma, and infiltrating leukocytes that contribute to a rich milieu of inflammatory 
cytokines, growth factors, chemokines, and other soluble factors.  In addition to these actively 
secreted factors, tumor cell death via necrosis further contributes to the altered environment by 
releasing endogenous danger signals.  Beyond the immediate tumor microenvironment, some of 
these factors have been detected at abnormal levels within the sera of individuals bearing tumors.  
Because the JAK/STAT and MAP kinase pathways are exceptionally sensitive to cytokines, 
growth factors, and stress/inflammation, it is likely that the presence of tumor and its associated 
alterations in protein expression will affect these signaling pathways within normal, circulating 
leukocytes. 
 Alterations in cytokine expression are exhibited in many types of cancer; either as a result 
of tumor cell production or surrounding/infiltrating cells, including stromal cells and 
 42
inflammatory leukocytes.  For instance, patients with advanced stages of breast cancer often 
have higher than normal serum levels of TNFα and IL-1β [99].  Presumably, these cytokines are 
often secreted by tumor-associated macrophages (TAMs).  Additionally, VEGF expression is 
markedly increased in breast cancer cells and their reactive stromal cells [100].  In patients with 
head and neck squamous cell carcinoma (HNSCC), IL-6, IL-8, and VEGF concentrations in the 
serum of patients are higher when compared with controls [101].  Serum levels of IL-6 are also 
elevated in patients with colorectal [36], cervical [41], epithelial ovarian [43], and prostate 
cancer [37], as well as in those with metastatic renal cell [42] and esophageal squamous cell 
carcinoma [102] and Hodgkin’s Disease [103].  In several types of cancer, colorectal [36], 
metastatic melanoma [38], endometrial [40], and hepatocellular carcinoma [39], IL-8 serum 
concentrations are also elevated.  Another cytokine, IL-7, is elevated in the serum of Hodgkin’s 
Disease patients and correlates with advanced stage [103].  In other instances, endogeneous 
danger signals, such as HMGB1, uric acid, ATP, adenosine, S100 molecules, and heat shock 
proteins (HSPs), are elevated in cancer patients.  These factors are often overexpressed in tumors 
and are released when they undergo necrotic cell death [104].  Most of these factors, exhibiting 
unbalanced expression within the setting of cancer, are capable of activating the JAK/STAT and  
MAP kinase pathways.  Therefore, it is likely that analyzing phosphorylation states of proteins 
within these pathways will become a useful tool in the immunodiagnosis of cancer or in the 
monitoring of its treatment.   
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2.5.3 Signaling defects within “normal” PBMC in the setting of cancer 
 
Although very few groups have studied the JAK/STAT and MAP kinase signaling pathways 
within “normal” PBMC in individuals with cancer, there is evidence to suggest that these 
pathways and others are abnormal.  These studies strengthen the hypothesis that the effects of 
factors released by tumors, their supporting cells, and activated leukocytes extend beyond the 
tumor microenvironment.  One of the most studied defects in circulating PBMC isolated from 
cancer patients is the loss or reduction of T-cell receptor (TCR) zeta (ζ)-chain, which is 
associated with impaired immune function.  The ζ-chain is a subunit of the TCR in T cells and 
CD16 in NK cells, primarily responsible for signal transduction [105].  Compared to normal 
controls, ζ-chain is significantly decreased in CD4 and CD8 T cells, and CD16 NK cells from 
many HNSCC patients, with the degree of reduction correlating with cancer aggressiveness 
[106].  Additionally, decreased expression of ζ-chain was found in tumor-infiltrating 
lymphocytes (TIL) and peripheral blood lymphocytes (PBL) from many oral carcinoma patients 
[107].  Likewise, decreases in ζ-chain were observed in peripheral blood T cells from patients 
with advanced metastatic melanoma [108], advanced gastric cancer [109], breast cancer [110], 
colorectal cancer, renal cell carcinoma, prostate cancer, hepatic cancer, and Hodgkin’s 
lymphoma [111].  Similarly, decreases in p56lck, a tyrosine kinase associated with CD4, CD8, 
and IL-2Rβ, are observed in PBMC from patients with various types of cancer [111].  It should 
be noted, however, that most of these defects in p56lck and ζ-chain were only detected in patients 
with very advanced cancer and the mechanisms by which these changes occur are not well 
understood.  By observing high serum levels of 8-isoprostrane, a product of lipid oxidation and 
marker for oxidative stress, and large numbers of activated granulocytes in the peripheral blood 
of cancer patients, it is believed that H2O2 production from these cells may be partly responsible 
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for these effects [112].  Because IL-8 is often elevated in the serum of cancer patients, as 
previously described, it is possible that this is responsible for granulocyte activation.  Though 
few studies have examined signaling downstream of the ζ-chain in cancer patients, it is likely 
that the MAP kinase pathway will be affected, as it is involved in TCR signaling [113].   
Other studies suggest abnormal activation of another major signaling pathway, NFκB, 
within PBMC from cancer patients.  T cells from many renal cell carcinoma patients had 
abnormal NFκB activation following anti-CD3/ionomycin treatment, characterized by a failure 
of RelA, p65, to translocate from the cytoplasm to the nucleus [114].  This study also 
demonstrated that impaired NFκB activation did not correlate with decreased ζ-chain expression.  
In another study, peripheral blood T lymphocytes from breast cancer patients exhibited impaired 
ability to translocate RelA, p65, following anti-CD3 and IL-2 stimulation despite normal 
cytoplasmic levels of p65 [110].  T lymphocytes from some of these patients displayed increases 
in MKP-1, a MAP kinase phosphatase, suggesting impairments in MAP kinase signaling as well.  
It is also noteworthy that NFκB impairment is induced in healthy T cells by incubating them 
with supernatants from renal tumor explants [114].   
With regard to dysfunctional JAK/STAT signaling within PBMC acquired from cancer 
patients, very few studies have been performed.  In an experiment, where T and B cells were 
purified from mice with mammary adenocarcinoma, marked decreases in STAT5a and STAT5b, 
and to a lesser extent, their mRNA, were observed [115].  These lymphocytes were also impaired 
in their ability to generate antigen-specific cellular and humoral immune responses.  In another 
study, STAT1 phosphorylation was evaluated in PBMC from melanoma patients and healthy 
donors following in-vitro IFNα treatment.  Compared to melanoma patients, healthy donors had 
higher basal levels of STAT1 phosphorylation in total PBMC, T cells, and NK cells.  However, 
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total STAT1 levels between the cancer patients and volunteers were equivalent.  Additionally, 
there were no differences in pSTAT1 following in vitro stimulation with IFNα [116].  These 
studies suggest that signaling pathways within “normal” PBMC isolated from cancer patients are 
aberrant, perhaps as a consequence of the altered cytokine milieu.  As the previous example 
indicates, it is possible that factors chronically released in the setting of cancer may lead to the 
upregulation of negative regulators of signaling.  Therefore, analyzing the activation states of 
signaling pathways, including the JAK/STAT and MAP kinase pathways, may be valuable tools 
for diagnosing the presence of cancer or other inflammatory conditions, as well as monitoring 
the progress of treatment regimens.   
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3.0 SPECIFIC AIMS OF THESIS 
 
 
 
Although the enumeration and phenotyping of peripheral blood cells has proven successful for 
the diagnosis and evaluation of many clinical conditions, its value is limited.  Combining 
measurements of cell function together with immunophenotyping should provide researchers and 
clinicians with greater information, enabling them to better diagnose and evaluate patients.  In 
contrast to common measurements of function, which require prolonged culturing conditions and 
lengthy protocols that can introduce artifacts; analysis of activated signaling pathways via 
protein phosphorylation is a rapid technique.  By analyzing peripheral blood mononuclear cells 
(PBMC), which are readily obtainable and act as cellular biosensors through their role in 
immune surveillance, scientists and clinicians could potentially deduce information about the 
pathological environs that they encounter while circulating through the body.  Use of a platform 
to analyze PBMC on a cell-by-cell basis, such as flow cytometry, rather than conventional bulk 
analysis methods, greatly enhances the data obtained, as PBMC are comprised of a variety of 
cellular subsets, each with the ability to respond differently to its environment.  Because tumors 
and other inflammatory conditions alter the milieu of cytokines and other factors in the serum, it 
is likely that PBMC will display abnormal signaling or be defective in their ability to respond to 
stimuli.  In this regard, a flow cytometric assay to detect phosphorylation of signal transduction 
pathways within PBMC should be a valuable tool for the diagnosis and/or monitoring of patients 
with cancer and other clinical states.      
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3.1 SPECIFIC AIM 1 
 
Our first specific aim is to characterize the phosphorylation of STAT1, STAT3, STAT5b, 
STAT6, p38 MAPK, and ERK1/2 in total PBMC via flow cytometry following in-vitro cytokine 
treatment in a time and dose-dependent manner.  Taking advantage of their differences in size 
and granularity, responses of lymphocytes and monocytes will be analyzed separately, gating on 
each population based on their forward and side-scatter properties.  Additionally, results will be 
compared to those obtained by Western blotting.  These experiments will be used to determine 
conditions that induce maximal phosphorylation within PBMC.  
   
Hypothesis 1a: Phosphorylation of these signaling molecules will 
increase as the concentration of stimulus increases and 
phosphorylation will occur rapidly followed by a reduction over 
time.       
 
Hypothesis 1b: Differences will be detectable between lymphocytes and 
monocytes regarding phosphorylation of a given protein with a 
given stimulus. 
   
Hypothesis 1c: Protein phosphorylation data obtained by flow cytometry will 
correlate with results obtained by Western blot. 
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3.2 SPECIFIC AIM 2 
 
Specific aim 2 is to develop flow cytometric methodology enabling the simultaneous detection of 
cell surface proteins used to immunophenotype PBMC subsets and intracellular phosphorylated 
proteins: STAT1, STAT3, STAT5b, STAT6, p38 MAPK and ERK1/2.  A panel of 
permeabilizing agents with varying concentrations will be used to determine a suitable condition 
for dual staining.  These experiments will use stimulation conditions obtained in aim 1 to 
characterize protein phosphorylation pathways within major subsets of PBMC: CD4+ and CD8+ 
T cells, CD19+ B cells, CD56+ NK cells, and CD14+ monocytes.  Additionally, experiments will 
be performed to assess variability when using this assay to analyze signaling within multiple 
draws from the same individual and in several different individuals. 
      
Hypothesis 2a: Using a milder permeabilization/denaturing agent , such as diluted 
alcohols, will preserve cell surface epitopes while retaining the 
ability to stain intracellular phospho-epitopes. 
 
Hypothesis 2b: Because NK cells and monocytes are associated more with rapid, 
innate immune responses, these cells will become phosphorylated 
to a greater degree than T and B lymphocytes following cytokine 
stimulation.  
 
Hypothesis 2c: Variability in phosphorylation following stimulation within a 
single, normal donor or between multiple, normal donors will be 
minimal.
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4.0 FLOW CYTOMETRIC CHARACTERIZATION OF PROTEIN 
PHOSPHORYLATION PATHWAYS IN HUMAN PBMC 
 
 
 
4.1 ABSTRACT 
 
Current strategies designed to assess cells in the peripheral blood are limited to evaluation of 
phenotype or delayed measurement [>6hours] of function, usually quantifying cytokine 
production, cytolytic activity, or response to antigens. We reasoned that measurable 
abnormalities in signaling pathways could reflect pathological environs that cells experience in 
the setting of inflammatory states/cancer and could be represented in the peripheral blood.  Two 
major pathways regulating the immune response are the JAK/STAT and MAPK/ERK pathways.  
These pathways are initiated by ligand-receptor binding, and are rapidly propagated by 
subsequent protein phosphorylation cascades.  We evaluated the brief application of cytokines 
in-vitro to interrogate the early phosphorylation events of these signaling pathways in normal 
peripheral blood mononuclear cells (PBMC).  Individual cytokine doses and time intervals of 
treatment were assessed to identify conditions useful in a clinical laboratory and as an initial 
goal, to induce maximal phosphorylation.  Surprisingly, all of the STAT proteins assessed and 
ERK1/2 are maximally phosphorylated within 15 minutes in human PBMC simply following 
addition of cytokines without preactivation of the cells.  At two hours, cells typically return to 
their basal phosphorylation states.  For most of the cytokines tested, increased phosphorylation 
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directly correlated with increased concentrations of the individual cytokines.  These strategies 
will enable robust development of simple blood analyses to identify normal levels as well as 
impairments in STAT and MAPK/ERK signaling pathways associated with various human 
disease states including acute and chronic inflammatory conditions throughout clinical 
immunology. 
 
 
 
4.2 INTRODUCTION 
 
The development of novel strategies for measurement of disease, so-called biomarkers and 
surrogates, has most recently focused primarily on serum proteomics and microarray assays 
[117]. Although leukocytes are readily separated and analyzed in the peripheral blood, most 
assessments have been limited to simple phenotyping and more extensive evaluations have been 
performed solely in research or specialty laboratories given the requirements for prolonged 
periods of incubation, sterile environments, and sophisticated measurement tools.  Simultaneous 
evaluation of phenotype and function of peripheral blood lymphocytes has provided important 
insights for clinicians and scientists in the areas of infectious disease [1-4], autoimmunity [5, 6], 
and cancer [7-11].  Pure immunophenotyping, however, is of limited value in the assessment of 
clinical states.  Most functional assays, which could be utilized in conjunction with phenotyping, 
are tedious or require extensive culturing periods.  One simple, yet information-dense, approach 
is to examine signaling pathways within individual peripheral blood cells following cytokine or 
mitogenic stimulation.  Abnormalities in signaling pathways can provide clues to disorders  
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related to pathological environments that cells experience while emigrating from the bone 
marrow and recirculating from tissues and lymph nodes or emergent from altered serum 
cytokines [118].       
Traditionally, cell signaling analysis has been performed using Western blots on large 
populations of homogeneous cells.  The data obtained is an average of all of the cells analyzed.  
If performed on a complex mixture of cells, such as peripheral blood mononuclear cells (PBMC), 
such a technique would not yield signaling information of individual cellular subsets within the 
total population.  The advent of flow cytometry allowed us to perform cell signaling analysis on 
individual cells, thus resolving signaling events within previously obscure subsets of cells [119, 
120].  Additionally, signaling analysis using flow cytometric methods correlates very well with 
other established techniques [69, 116].   
 Most signaling pathways are initiated by ligand-receptor binding and are propagated by 
subsequent protein phosphorylation cascades.  These phosphorylation events occur very rapidly 
following receptor engagement.  With the introduction of antibodies having specificity for 
phosphorylated epitopes of proteins and intracellular staining techniques, very proximal 
signaling events can be captured that were previously inaccessible.  One important pathway in 
the regulation of immune responses is the JAK/STAT pathway.  This pathway is important in 
host defense, growth control, and apoptosis [21, 26, 121].  Within cancer cells, signaling through 
many STAT proteins is dysfunctional [33, 35, 122, 123].  Another major pathway driven by 
protein phosphorylation is the MAPK/ERK pathway.  It regulates cell cycle progression, 
apoptosis, cytokine production, RNA splicing, and cell differentiation in response to stress, 
inflammation, and other stimuli [24, 86, 87].  The MAPK pathway is activated within many 
cancers, promoting it as either a cause or consequence of tumor progression [32, 34, 124, 125].    
 52
 We evaluated the brief application of cytokines and mitogens in-vitro to interrogate the 
signaling pathways of normal PBMC and analyzed the early phosphorylation events of 
important, available signaling proteins within the JAK/STAT, and MAPK/ERK pathways: 
STAT1, STAT3, STAT4, STAT5, STAT6, ERK1/2, and p38 MAPK.   The individual cytokine 
doses and time intervals of treatment were assessed to identify conditions for maximal 
phosphorylation.  Addtionally, due to the differences in light scatter between monocytes and 
lymphocytes, we were able to evaluate their responses separately without the use of additional 
reagents.   It should be noted that the phosphorylation events assessed in these studies were 
obtained on two different cytometers.  Where appropriate, we have indicated which cytometer 
was used to obtain the data.  We provide qualitative data concerning dose responses and kinetics 
of phosphorylation for many proteins within the JAK/STAT and p38 MAPK families, as well as 
differential responses to stimuli in distinct PBMC populations.  Although the results are not 
quantitatively comparable between cytometers, the observation that most of the proteins 
qualitatively follow robust and similar kinetics of phosphorylation serves to verify the assay’s 
reproducibility.  Furthermore, our data indicate that this assay is extremely reproducible within a 
single experiment.  The techniques developed offer a rapid approach for evaluating protein 
phosphorylation within normal PBMC and will have broad applicability in assessing patients 
with cancer [117] and other inflammatory states [126-128]. 
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4.3 MATERIALS AND METHODS 
 
4.3.1 Reagents   
 
PBMC were isolated from normal, volunteer donor whole blood at the University of Pittsburgh 
using Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden) in accordance with an 
approved IRB protocol (IRB #960279, UPCI #86-22.)  ACK buffer (0.15M NH4Cl, 10mM 
KHCO3, 0.1mM NaEDTA; pH 7.2-7.4) was used to lyse remaining red blood cells (RBC).  
PBMC were stored in freeze medium (90% FBS, 10% DMSO) in liquid nitrogen.  IFNγ, IL-2, 
IL-3, IL-6, IL-10 (R&D systems, Minneapolis, Minnesota), IFNαA, IL-4 (Biosource, Camarillo, 
California), IL-7 (Biodesign International, Saco, Maine), phorbol 12-myristate 13-acetate (PMA) 
(Sigma, Saint Louis, Missouri) and IL-13 (IDM, Paris, France) were used to stimulate cell 
signaling pathways.  IMDM (Mediatech, Herndon, Virginia) was the medium used during 
cytokine treatment.  2% paraformaldehyde (Fisher Scientific, Pittsburgh, Pennsylvania) was 
prepared in Dulbecco’s PBS (Mediatech, Herndon, Virginia).  90% methanol (Fisher Scientific, 
Pittsburgh, Pennsylvania) in PBS at -20°C was used to permeabilize the PBMC.  Primary 
antibodies: pSTAT1(Y701):PE, pSTAT3(Y705): PE, pSTAT5(Y694):PE, pSTAT5(Y694), 
pSTAT6(Y641):Alexa488, pSTAT6(Y641):A647, pERK1/2(T202/Y204):PE, p-p38 
MAPK(T180/Y182):PE (Becton Dickinson, Franklin Lakes, New Jersey) were used to label 
phosphorylated proteins.  Rabbit anti-STAT5 used to label total protein for Western blotting was 
obtained from (Santa Cruz Biotechnology, Santa Cruz, CA.)  The PBMC were analyzed on a 
FACScan flow cytometer or FACSArray (Becton Dickinson) in FACS buffer (PBS, 10% FBS, 
0.1% azide, 0.1% glucose).  Sphero rainbow fluoresecent particles (Becton Dickinson) were used 
to calibrate the flow cytometer before analysis where indicated.  CellQuest software (Becton 
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Dickinson) was used during acquisition of the samples on the FACScan and FACSDiva software 
(Becton Dickinson) was used for acquisition on the FACSArray.  Off-line analysis was 
performed using FACSDiva software.  
 
4.3.2 Isolation of PBMC 
 
10mL of Ficoll-Paque Plus was pipetted into the bottom of a centrifuge tube containing 20 mL of 
whole blood and 20 mL of PBS to set up a density gradient.  The blood was spun at 400Xg for 
30 minutes.  PBMC were pipetted off into a new centrifuge tube.  The cells were spun into a 
pellet at 400Xg for 10 minutes.  5 mL of ACK buffer was added to the cells for 15 minutes at RT 
to lyse remaining RBC.  The cells were pelleted and resuspended in IMDM.  Cells were counted, 
spun, and resuspended in freeze medium at a concentration of 107 cells/mL.  107 PBMC were 
placed into individual cryogenic vials (Corning, Corning, New York).  The PBMC were kept at -
80°C for one day and were then transferred to a liquid nitrogen freezer until needed. 
 
4.3.3 Preparation of PBMC for flow cytometry  
  
PBMC were removed from liquid nitrogen and were thawed in a 37°C water bath.  Freeze 
medium was removed and the cells were resuspended in IMDM.  5x105 PBMC in 50μl of media 
were pipetted into separate centrifuge tubes for FACScan analysis or wells of a 96-well 
polypropylene plate for FACSArray analysis.  For dose response experiments, cells were treated 
with increasing doses of various cytokines.  The PBMC were left to incubate with the cytokines 
at 37°C for 15 minutes.  For time course experiments, the PBMC were treated with the dose of 
cytokine found to cause maximal phosphorylation in the dose response experiments.  The 
treatment was left at 37°C for 5, 10, 15, 30, 60 and 120 minutes.  At the end of the treatment, the 
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PBMC were spun and the supernatant was discarded.  2 % paraformaldehyde was added to 
achieve a final concentration of 1% and was left at RT for 10 minutes to fix the PBMC.  The 
fixative was removed by centrifugation.  PBS was used to wash out residual fixative.  90% 
methanol was added to permeabilize the cells at -20°C for 10 minutes.  PBS was used again to 
wash out residual methanol.  The cells were blocked with isotype IgG at 10 μg/ml in FACS 
buffer for 15 minutes at RT.  After centrifugation, the cells were resuspended in 50 μL of FACS 
buffer.  For experiments using fluorophore-conjugated primary antibodies, 7 μL of antibody was 
added to 50 μL of PBMC and was left in the dark at RT for 30 minutes.  After incubation with 
antibody, cells were washed with PBS + 0.2% Tween-20 for 10 minutes to eliminate non-
specific binding.  Labeled cells were pelleted and resuspended in 300 μL of FACS buffer for 
flow cytometric analysis. 
   
4.3.4 Western blotting of total and phospho-STAT   
 
PBMC are first magnetically separated into lymphocytes and monocytes using MACS CD14 
positive selection (Miltenyi Biotec, Auburn, CA.) according to the manufacturer’s suggestion.  
Monocytes and lymphocytes were either left untreated in IMDM or were treated with IL-2 at 10, 
100, or 1000 IU/ml for 15 min at 37°C for dose response experiments.  For time course 
experiments, monocytes and lymphocytes were left untreated as before or were treated with IL-2 
at 1000 IU/ml for 15, 30, 60, or 120 min at 37°C.  Whole cell lysates were prepared by 
incubating the cells in lysis buffer (100 mM NaCl, 10 mM Tris (pH 87.4), 1% NP-40, 
phosphatase inhibitor cocktail I and II (Sigma, St. Louis, MO)) for 15 minutes.  Following lysis, 
a BCA assay (Pierce Biotechnology, Rockford, IL) was performed to analyze total protein 
concentration within each of the lysates.  Lysates were boiled for 5 minutes in XT buffer (Bio-
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Rad Laboratories, Hercules, CA) containing 10% β-mercaptoethanol.  The samples were loaded 
into Criterion XT precast gels (Bio-Rad Laboratories, Hercules, CA) at 10μg per lane.  Proteins 
were separated by gel electrophoresis at 100V for 1.5 hours.  The proteins were then transferred 
to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA) at 100V for 45 minutes.  
After blocking the membranes in TBS containing 1% BSA overnight at room temperature, the 
membranes were probed with mouse anti-pSTAT5 at a 1:500 dilution or rabbit anti-STAT5 at a 
1:200 dilution for 1 hour at room temperature under constant agitation.  After three 10 minutes 
washes with TBS containing 0.2% Tween-20, the blots were probed with HRP-conjugated 
donkey-anti-mouse IgG at 10 ng/ml for 1 hour at room temperature under constant agitation.  
The blots were washed three times with TBS containing 0.2% Tween-20.  Supersignal West Pico 
Chemiluminescence Substrate (Pierce Biotechnology, Rockford, IL) was added to the blots 
according to the manufacturer’s instructions.  After exposing the pSTAT5 blot to x-ray film for 
10 min and the STAT5 blot for 30 seconds, the film was developed using a Kodak X-OMAT 
2000A processor.  
 
4.3.5 Flow cytometric analysis of phospho-proteins   
 
The samples were analyzed on a FACScan or FACSArray flow cytometer.  CellQuest software 
was used for the acquisition of events on the FACScan and FACSDiva software was used for 
acquisition on the FACSArray.  10,000 gated events were collected for each sample.  Off-line  
analysis was performed using FACSDiva software.  Within FACSDiva, a monocyte and 
lymphocyte gate was created based on forward and side scatter properties.  For each of these 
gated populations, the geometric mean fluorescence intensity was analyzed. 
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4.4 RESULTS 
 
4.4.1 Dose and time-dependent responsiveness of STAT1 phosphorylation in cytokine  
stimulated PBMC 
 
PBMC (5x105 in 50 μl) were treated with IFNγ or IFNα at concentrations of 10, 100, or 1000 
IU/mL or were left untreated in IMDM alone.  During cytokine treatment, the PBMC were 
incubated at 37°C for 15 minutes.  Panel A of Figure 7 displays the level of STAT1 
phosphorylation represented as geometric mean fluorescence intensity (GMFI) as measured by 
flow cytometry on a BD FACScan.  The responsiveness of PBMC to IFNγ, even at low 
concentrations (10 IU/mL), is primarily within the monocyte gate, with very little 
phosphorylation of STAT1 in the lymphocyte population.  The entire monocyte population 
increased expression of pSTAT1 following treatment, as shown in panel C, whereas the 
lymphocyte population was unresponsive.  The necessary concentration of IFNγ as a stimulus for  
maximal STAT1 phosphorylation is 100 IU/mL.  IFNα exhibits a dose-dependent effect on 
STAT1 phosphorylation within PBMC, also primarily within the monocyte gate, with the 
necessary concentration for maximal STAT1 phosphorylation being 1000 IU/mL.  Once again, 
the entire monocyte population increased pSTAT1, whereas the lymphocytes produced a 
bimodal peak, as shown in panel D.    At low concentrations (10 IU/mL), IFNα is not as effective  
as IFNγ at eliciting STAT1 activation.  To analyze the kinetics of STAT1 phosphorylation, 
PBMC were treated with 100 IU/ml and 1000 IU/ml of IFNγ and IFNα respectively for 5, 10, 15,  
-30, 60, and 120 minutes at 37°C and were analyzed on a BD FACScan in separate experiments.   
Panel B of Figure 7 illustrates the time-course experiment depicting STAT1 phosphorylation as 
GMFI in PBMC following treatment with IFNγ and IFNα.  Once again, IFNγ exerted its effects  
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Figure 7. Interferons (α and γ) induce rapid phosphorylation of STAT1 in PBMC, 
primarily in monocytes, in a dose-dependent manner.  PBMC were stimulated with 
varying concentrations of IFNγ or IFNα for 15 min at 37°C (panel A) and with 100 
IU/ml of IFNγ or 1000 IU/ml of IFNα for the indicated time intervals (panel B).  STAT1 
phosphorylation is expressed as the geometric mean fluorescence intensity of pSTAT1-
PE within gated [by size and granularity] monocyte and lymphocyte populations as 
measured by flow cytometry.  Panels C and D indicate STAT1 phosphorylation in 
untreated cells (filled histograms) and cells treated for 15 min with 100 IU/ml of IFNγ or 
1000 IU/ml of IFNα (unfilled histograms) respectively.    Note the rapid 
phosphorylation following stimulation and subsequent loss of phosphorylation at late 
time points, as well as the differential activation of monocytes and lymphocytes.  Each 
experiment was performed on a separate day on a BD FACScan with cells from 
different draws. 
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on the monocyte population alone, with maximal phosphorylation occurring very rapidly (< 5 
minutes).  The level of STAT1 phosphorylation decreased steadily, approaching baseline levels 
over the two-hour time frame.  Stimulation with IFNα caused activation of STAT1 within both 
cell populations, but primarily in monocytes.  Following IFNα treatment, maximal 
phosphorylation of STAT1 occurred at 10 to 15 minutes.  At later time points, levels of 
phosphorylation decreased to baseline.  The actual magnitude of response is not the same in 
panels A and B even though both experiments were analyzed on the same cytometer, but we 
attribute this difference to performing the experiments without prior voltage calibration of the 
instruments.  It is also likely that there will be some variability in the cellular response between 
normal donors or even the same donor on different dates.  
  
4.4.2 Dose and time-dependent responsiveness of STAT3 phosphorylation in cytokine 
stimulated PBMC 
 
PBMC (5x105 in 50 μl) were left untreated with IMDM or were treated with IL-10 or IL-6 at 
concentrations of 1, 10, and 100 ng/mL or IFNα at concentration of 10 IU/ml, 100 IU/ml, or 
1000 IU/ml for 15 minutes at 37°C to induce STAT3 phosphorylation.  Panel A of Figure 8 
demonstrates the relationship between STAT3 phosphorylation and cytokine concentration in 
monocytes and lymphocytes as assessed by GMFI on a BD FACScan.  IL-6 titration experiments  
were not performed in the same experiment, so the responses should not be compared to those of 
the other cytokines.  With the cytokines evaluated, STAT3 activation appears to occur within 
both monocytes and lymphocytes.  There is a clear dose-dependent response of pSTAT3 to IL-6, 
with activation occurring at concentrations as low as 1 ng/mL with maximal activation at 100 
ng/mL.  IFNα and IL-10 both activated STAT3 with maximal levels attained at concentrations of 
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100 IU/ml and 10 ng/mL respectively.  In contrast to the STAT1 experiments, the entire 
monocyte and lymphocyte populations increased expression of pSTAT3 for each of the 
cytokines evaluated (data not shown.)   To analyze the kinetics of STAT3 phosphorylation, 
PBMC were treated with IMDM as a control, IL-10 (10 ng/mL), IFNα (100 IU/mL), or IL-6 (50 
ng/mL).  The results are indicated in panel B of Figure 8.  IL-6 treated cells were assessed in a 
separate experiment and were analyzed using a BD FACSArray, whereas other samples were 
analyzed on a BD FACScan.  Following IFNα and IL-10 treatment, maximal phosphorylation of 
STAT3 occurs rapidly by 10 minutes.  STAT3 phosphorylation decreases towards baseline 
values as the incubation time with both cytokines approaches two hours.  When PBMC are 
stimulated with IL-6, phosphorylation of STAT3 increases to maximal levels by 15 minutes.  At  
later time points, pSTAT3 levels approach baseline, but appear to increase again at the two hour 
time point. 
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Figure 8. Following cytokine treatment (IL-10, IFNα, and IL-6) phosphorylation of 
STAT3 is transiently induced in a dose-dependent manner.  PBMC were stimulated 
with varying concentrations of IL-10, IFNα (concentration in parentheses), or IL-6 for 
15 min at 37°C (panel A) or with 10 ng/ml of IL-10, 100 IU/ml of IFNα, or 50 ng/ml of 
IL-6 for the indicated time intervals (panel B).  STAT3 phosphorylation is expressed as 
the geometric mean fluorescence intensity of pSTAT3-PE within monocyte and 
lymphocyte populations as measured by flow cytometry.    Responsiveness is transient 
and generally has returned towards baseline by two hours following stimulation.  All 
experiments in panel A were performed on a BD FACScan, but the IL-6 experiment was 
performed in a separate experiment with cells from a different separation and date from 
the same normal donor.  In panel B, all experiments were performed on a BD FACScan 
in the same experiment except for the IL-6 experiment, which was performed separately 
on a BD FACSArray (explains the difference in GMFI.)    
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4.4.3 Dose and time-dependent responsiveness of STAT5 phosphorylation in cytokine 
stimulated PBMC 
 
IL-3 at concentrations of 1, 10, and 100 IU/mL was used to stimulate 5x105 PBMC in 50 μl for 
15 minutes at 37°C.  As a control, cells were incubated with IMDM.  In a separate experiment, 
the cells were treated with IL-7 at concentrations of 1, 10, and 100 ng/mL under the same 
conditions.  Cells were analyzed for pSTAT5 by recording GMFI on a BD FACScan for the dose 
response experiments.  Panel A of Figure 9 illustrates the dose response relationship of pSTAT5  
following stimulation.  IL-3 induces dose-dependent responses in pSTAT5 within the entire 
monocyte population exclusively.  The differential effects of IL-3 on monocytes and 
lymphocytes is shown in panel C of Figure 9.  Of the concentrations tested, 100 IU/mL of IL-3 
was sufficient for maximal pSTAT5 induction.  On the other hand, monocytes were 
unresponsive to IL-7, but approximately 50% of lymphocytes increased pSTAT5, as shown in 
panel D of Figure 9.  This bimodal peak is similar to that observed for STAT1 phosphorylation 
in lymphocytes following IFNα treatment.  STAT5 was phosphorylated in lymphocytes even at 
the lowest concentration of 1 ng/mL, while increasing concentrations did not appear to have any 
greater effect.  Time-course experiments were performed by treating PBMC with 100IU/ml of 
IL-3, or 50 ng/mL of IL-7 at 37°C for 5, 10, 15, 30, 60, and 120 minutes.  IL-3 was assessed on 
the BD FACScan, while the IL-7 experiment was analyzed on the BD FACSArray.  This 
explains the large difference in baseline GMFI.  Phosphorylation kinetics following treatment are 
displayed in panel B of Figure 9.  As expected, STAT5 phosphorylation does not increase above 
baseline in the monocyte population with IL-7 treatment.  However, lymphocytes rapidly 
phosphorylate STAT5 within 5 minutes of treatment.  Unlike previous data, the levels of  
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Figure 9. IL-3 and IL-7 induce phosphorylation of STAT5 in different PBMC 
populations.   PBMC were stimulated with 0, 1, 10, or 100 IU/ml of IL-3, or 0, 1, 10, or 
100 ng/ml of IL-7 for 15 min at 37°C (panel A) or treated with 100 IU/ml of IL-3, or 50 
ng/ml of IL-7 for the indicated time intervals (panel B).  STAT5 phosphorylation is 
expressed as GMFI or log2(GMFI) of pSTAT5-PE within monocyte and lymphocyte 
populations as measured by flow cytometry.  Panels C and D show STAT5 
phosphorylation in untreated cells (filled histograms) and cells treated for 15 min with 
100 IU/ml of IL-3, or 50 ng/ml of IL-7 for 2 hours (unfilled histograms) respectively.  
Interestingly, IL-7 mediated prolonged activation and induced phosphorylation in 
lymphocytes alone, whereas that with IL-3 was only transient and exclusively in 
monocytes.  All experiments were performed on a BD FACScan, except the time-course 
experiment involving IL-7, which was performed separately on a BD FACSArray 
(explains increased GMFI.)  The dose and time course experiments were not performed 
in the same experiment. 
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phosphorylation do not quickly decay towards baseline over the two-hour treatment.  Whereas 
lymphocytes were unresponsive to IL-3, monocytes phosphorylated STAT5 to maximal levels at 
10 minutes following treatment with a subsequent decrease in pSTAT5 towards baseline at later 
time points.  This differential responsiveness of monocytes and lymphocytes to individual 
cytokines/stimuli allows inferences regarding the earliest events in inflammation occurring 
rapidly within circulating cells. 
To verify that this assay is specifically detecting phosphorylated proteins within distinct 
cell populations, a Western blot experiment was performed in parallel with flow cytometry.  
Because a Western blot is a bulk analysis method, and therefore unable to distinguish between 
different cell types, PBMC were magnetically separated into lymphocytes and monocytes via 
CD14 positive selection prior to stimulation.  Cells were either left untreated or were treated with 
a dose response of IL-2 at 10, 100, or 1000 IU/ml for 15 min at 37°C.  In a separate experiment, 
cells were untreated or treated with 1000 IU/ml of IL-2 for 15, 30, 60, or 120 min at 37°C.  Cell 
lysates were blotted for either pSTAT or total STAT5.  The upper panel of Figure 10A illustrates 
the results of the Western blot.  The bands in the upper row represent pSTAT5 within 
lymphocytes and monocytes, while the lower band depicts total STAT5.  It is clear that untreated 
lymphocytes and monocytes, as well as IL-2 treated monocytes do not contain any 
phosphorylated STAT5 or it is below the limits of detection.  However, lymphocytes treated with 
IL-2 show an increase in phosphorylation, as indicated by the band intensities, with increasing 
IL-2 concentration.  Unseparated PBMC were simultaneously treated for IL-2 in triplicate and 
were analyzed in parallel using the BD FACSArray cytometer for STAT5 phosphorylation.  In 
the lower panel of Figure 10A, the median pSTAT5 GMFI of the triplicate wells is plotted for 
each concentration of IL-2 within lymphocyte and monocyte populations.  The error bars  
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Figure 10. Differential responsiveness of STAT5 to IL-2 in lymphocytes and 
monocytes is verified via Western blot and flow cytometry.  In the upper portion of 
panel A, PBMC were separated into lymphocytes and monocytes prior to IL-2 
stimulation.  PBMC were treated with (1) IMDM or IL-2 at (2) 10 IU/ml, (3) 100 
IU/ml, or (4) 1000 IU/ml for 15 min.  In the upper portion of panel B, separated 
lymphocytes and monocytes were treated with (1) IMDM or 1000 IU/ml of IL-2 at (2) 
15 min, (3) 30 min, (4) 60 min, or (5) 120 min.  Lysates were blotted for pSTAT5 (top 
row) and total STAT5 (bottom row.)  The bottom portions of panels A and B, illustrate 
flow experiments run in parallel on the same day using triplicate wells on the BD 
FACSArray.  The median STAT5 GMFI is plotted and the GMFI of the remaining 
wells are plotted as error bars.  These experiments demonstrate strong correlation 
between western blotting and the flow cytometric assay, as well as high intra-
experimental reproducibility for the flow-based assay. 
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represent the GMFI of pSTAT5 from the two remaining wells.  This figure shows an obvious 
escalation in pSTAT5 following increasing concentrations of IL-2.  In the top panel of Figure 
10B, Western blot results from the IL-2 time course are provided.  Once again, the top row 
represents pSTAT5, while the bottom row represents total STAT5.  It is clear that there is an 
absence of pSTAT5 within unstimulated lymphocytes.  However, monocytes from this 
separation exhibited slight basal phosphorylation of STAT5.  This band does not increase with 
IL-2 treatment.  Within the lymphocyte population, there are strong bands corresponding to 
pSTAT5 following IL-2 stimulation.  These bands decrease at the two-hour time point, which is 
a trend that has been exhibited with many other signaling proteins in this manuscript.  The 
stronger band at 60 minutes is likely due to unequal protein loading, as evidenced by the thicker 
band for total STAT5 on the bottom row.  Unseparated PBMC were simultaneously treated for 
IL-2 in triplicate and were analyzed in parallel on a BD FACSArray cytometer for STAT5 
phosphorylation.  In the lower portion of Figure 10B, the median GMFI of pSTAT5 for the 
triplicate wells is plotted for each time point within lymphocyte and monocyte gates.  In 
agreement with previous data, there is no apparent increase in pSTAT5 following IL-2 within the 
monocyte population.  However, there is roughly a 4-fold increase in pSTAT5 within 
lymphocytes up to about 30 minutes following treatment, whereupon pSTAT5 levels decrease 
towards baseline.   To further highlight the validity of the flow cytometric results, the flow data 
from Figure 10 is included together with densitometry plots of the Western bands from Figure 10 
in the Appendix.  Thus, our flow cytometric assay correlates very well with results obtained by 
Western blot.  Moreover, it does not require a priori separation of cells to analyze subsets and 
allows for a greatly reduced protocol time.  Additionally, the coefficients of variation for the 
triplicate samples analyzed by flow cytometry are roughly 10% or less for all data points shown, 
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highlighting the intra-experimental reproducibility of this assay.  It should also be noted that 
voltage calibration was performed prior to analysis, which decreases the variation in 
fluorescence intensity between experiments. 
 
4.4.4 Dose and time-dependent responsiveness of STAT6 phosphorylation in cytokine 
stimulated PBMC 
 
IL-4 and IL-13 were applied at concentrations of 1, 10, and 100 ng/mL in individual experiments 
on 5x105 PBMC in 50 μl for 15 minutes at 37°C to induce STAT6 phosphorylation.  As a 
control, cells were incubated with IMDM under the same conditions.  Panel A of Figure 11 
demonstrates the level of pSTAT6 measured as GMFI on the BD FACScan following cytokine 
treatment.  IL-4 and IL-13 both induced dose-dependent responses in pSTAT6 levels in the 
entire monocyte population following treatment even at levels as low as 1 ng/mL.  The optimal 
concentration for stimulation tested is 100 ng/mL of either cytokine.  IL-4 also caused a dose-
dependent increase in pSTAT6 within the entire lymphocyte population.  On the other hand, 
lymphocytes were completely unresponsive to IL-13, consistent with previous findings [129, 
130].  Examples of the differential effects of these cytokines on STAT6 phosphorylation in 
lymphocytes and monocytes are shown in panels C and D of Figure 11.  Kinetics of STAT6 
phosphorylation were tested by treating PBMC with 100 IU/mL of IL-4 or 50 ng/mL of IL-13 in 
separate experiments for 5, 10, 15, 60, or 120 minutes at 37°C.  IL-4 experiments were analyzed 
using a BD FACScan while IL-13 experiments were analyzed separately on a BD FACSArray, 
which once again explains the large difference in GMFI.  Monocytes and lymphocytes were both 
rapidly phosphorylated by IL-4 with maximal phosphorylation occurring within 5 to 15 minutes, 
as shown in panel B of Figure 11.  Levels of pSTAT6 decrease comparatively slowly towards  
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Figure 11. TH2 cytokines IL-4 and IL-13 induce phosphorylation of STAT6 in a 
dose-dependent manner.  Human PBMC were stimulated with varying 
concentrations of IL-4 or IL-13 for 15 min at 37°C (panel A) or with 100 IU/ml of IL-
4 or 50 ng/ml of IL-13 for the indicated time intervals (panel B).  STAT6 
phosphorylation is expressed as GMFI of pSTAT6-A488 or log2(GMFI) of pSTAT6-
A647 within monocyte and lymphocyte populations as measured by flow cytometry.  
Panels C and D show STAT6 phosphorylation in untreated cells (filled histograms) 
and cells treated for 15 min with 100 IU/ml of IL-4, or 100 ng/ml of IL-13 (unfilled 
histograms) respectively. While IL-4 acted on both populations, IL-13 only activated 
the monocytes.  All experiments were performed on a BD FACScan, except for the 
IL-13 time course experiment, which explains the difference in GMFI.  Each of the 
dose and time-course experiments were performed on separate days. 
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baseline over the two-hour IL-4 treatment.  Once again, IL-13 produces no effect within the 
lymphocyte subpopulation, but quickly induces pSTAT6 within the monocytes.  Following IL-13 
treatment, maximal activation of STAT6 occured at 10 minutes and decreased toward baseline 
by two hours.  This assay could be useful in assessing specific small molecule and antibody 
strategies targeting either IL-4 or IL-13. 
   
4.4.5 Dose and time-dependent responsiveness of p38 MAPK and ERK1/2 phosphorylation 
in cytokine stimulated PBMC 
 
PBMC (5x105 in 50 μl) were either left untreated in IMDM or were treated with PMA at 
concentrations of 1nM, 10nM, 100nM, or 1μM for 15 minutes at 37°C.  GMFI of pp38 MAPK-
PE and pERK1/2-PE was measured with a BD FACSArray.  Panel A of Figures 12 and 13 
demonstrate the results of dose response experiments for p-p38 MAPK and pERK1/2 
respectively.  p38 MAPK phosphorylation increases steadily within the majority of the monocyte 
population as the concentration of PMA increases.  PMA does not, however, induce 
phosphorylation of p38 MAPK within the lymphocyte population.  These findings are illustrated 
in histograms in panel C of Figure 12.  On the other hand, ERK1/2 phosphorylation increases 
uniformly within both the monocyte and lymphocyte populations, as shown in panel C of Figure 
13.   Of the concentrations tested, maximal phosphorylation occurs at a PMA concentration of 
1μM.  The kinetics of p38 MAPK and ERK1/2 phosphorylation were examined by treating 
PBMC with 100 nM of PMA at 37°C for 5, 10, 15, 30, 60, or 120 minutes.  GMFIs of p-p38 
MAPK-PE and ERK1/2-PE were measured with a BD FACSArray and were plotted in panel B 
of Figures 12 and 13 respectively.  Once again, p38 MAPK was not phosphorylated within the 
lymphocyte population throughout the entire time course, confirming the previous results.   
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Figure 12. Prolonged phosphorylation of p38 MAPK by PMA within 
monocytes.  PBMC were stimulated with varying concentrations of PMA for 15 min 
at 37°C (panel A) or treated with 100 nM PMA for the indicated time intervals 
(panel B).  p38 MAPK phosphorylation is expressed as GMFI of pp38-PE within the 
monocyte and lymphocyte populations as measured by flow cytometry on a BD 
FACSArray.  Panel C shows p38 phosphorylation in untreated cells (filled 
histograms) and cells treated for two hours with 100nM PMA (unfilled histograms.)  
Only gated monocytes responded to PMA stimulation under these conditions.  The 
dose and time course experiments were performed on separate days.   
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Figure 13. Global phosphorylation of ERK1/2 in both monocytes and lymphocytes.  
PBMC were stimulated with varying concentrations of PMA for 15 min at 37°C (panel 
A) or treated with 100 nM PMA for the indicated time intervals (panel B).  pERK1/2 
phosphorylation is expressed as GMFI of pERK1/2-PE within monocyte and 
lymphocyte populations as measured by flow cytometry on a BD FACSArray.  Panel C 
shows ERK phosphorylation in untreated cells (filled histograms) and cells treated for 
15 min with 100nM PMA (unfilled histograms.)  Substantial increases in 
phosphorylation were observed in both populations.  The dose and time course 
experiments were performed on different days.   
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Unlike most signaling proteins examined in this study, p38 MAPK was increasingly 
phosphorylated over the entire two hour incubation period.  Conversely, maximum ERK1/2 
phosphorylation occured within 10 minutes in the monocyte population and decreased to levels 
lower than baseline at later time points.  The kinetics within the lymphocyte population differed 
as maximum phosphorylation was reached at 30 minutes, followed by decay towards baseline at 
1 and 2 hours. 
 
4.5 DISCUSSION
 
We have applied flow cytometric-based techniques to evaluate the cytokine-induced 
phosphorylation pathways [CIPP] of STAT1, STAT3, STAT5, STAT6, p38 MAPK, and ERK1/2 
in response to various concentrations and time-course treatments with a panel of cytokines.  
STAT proteins and ERK1/2 are rapidly phosphorylated within human PBMC, maximal 
activation normally occurring within 15 minutes.  Increased phosphorylation correlated with 
higher concentrations of the cytokines tested. At two hours, cells typically approached their basal 
phosphorylation states with the exception of pp38 in monocytes following PMA treatment and 
pSTAT5 in lymphocytes following IL-7 treatment.  Using human monocytes, Fleisher et. al 
found similar results with comparable concentrations of IFNγ to induce STAT1 phosphorylation 
[15].  That study was limited, however, to monocytes and analysis of pSTAT1.   Our results 
confirm these findings and extend them to further demonstrate that individual cytokines induce 
phosphorylation in specific cell types and cause differential activation kinetics.  For example, we 
show that IL-3, IL-13, and IFNγ exclusively activate monocytes in short-term culture, while IL-2 
and IL-7 solely activate lymphocytes using assessment of STAT5 signaling pathways.  
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By using a cytometric approach, the analysis time is significantly reduced when 
compared to Western blotting, fewer cells are required, and use of PBMC allows visualization of 
both monocytes and lymphocytes without the need for additional separation steps or reagents, 
enabling ready application in a clinical laboratory.  Western blotting and flow cytometry provide 
similar results when applied to phospho-protein analysis [19, 69, 116], as we have also 
demonstrated by examining STAT5 phosphorylation following IL-2 dose and time-course 
experiments in Figure 10.  However, compared to Western blotting, flow cytometry allows for 
less manipulation of cells and can allow one to identify cells with differences in responsiveness, 
rather than a mean value for the total cell population. Additionally, flow-based techniques allow 
one to examine rare populations of cells, such as plasmacytoid dendritic cells (PDCs) and 
myeloid dendritic cells (MDCs) [131].   
We validated this strategy using two individual cytometers: the Becton Dickinson 
FACScan and FACSArray.  As the GMFIs differed greatly depending on the instrument used, 
comparison between experiments is difficult, but the consistent patterns of activation for many of 
the signaling proteins examined, i.e. maximal phosphorylation within 15 minutes followed by a 
decrease at later time points, as well as verification of the results with Western blotting serve to 
illustrate the robustness of this strategy.  Additionally, the differential effects of cytokines on 
distinct cell populations were reproducible between different experiments, as well as on different 
cytometers.  The cytometers were not voltage calibrated before the early experiments, causing 
increased inter-experimental variability, and we thus now recommend this procedure as an 
important and necessary step before each experiment.  We have provided qualitative data 
comparing two different cytometers, demonstrating similar relative quantitative dose responses 
and kinetics of phosphorylation for many proteins within the JAK/STAT and p38 MAPK 
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families, as well as differential responses to stimuli in distinct PBMC populations.  Additionally, 
we show that the sample-to-sample variability within a single experiment is extremely low, as 
evidenced by the triplicate samples provided in Figure 10 with CVs approximately 10% or less 
for all data points.  Due to the large number of cells analyzed for each sample (approximately 
20,000), verification of the data by Western blot, reproducible patterns of phosphorylation 
kinetics observed with various stimuli, and the non-trivial increases in phosphorylation 
illustrated in the raw histograms following stimulation, we did not include any tests of statistical 
significance.  From the histograms that we have recently included, one can observe that the shift 
in fluorescence intensity (phosphorylation) is not trivial.  In most cases, the entire population can 
be seen to shift.  This taken with the observation that many of the proteins follow the same 
kinetics of phosphorylation, as well as verification of the data by Western blot, suggest that this 
flow-based technique represents a reproducible and meaningful way of analyzing 
phosphorylation events within complex cell populations.   Using a single cytometer for 
acquisition and calibrating it regularly before analysis can increase quantitative, inter-
experimental reproducibility.  The results obtained in these experiments suggest interesting 
strategies for titrating immunosuppressive or immunostimulatory reagents such as FK506, 
cyclosporine, rapamycin, IL-2, CTLA4 antibody, and possibly pathogen or damage associated 
molecular pattern molecules [PAMPs/DAMPs] including HMGB1[132] or CpG molecules.   
Acute and chronic inflammation can set up altered microenvironments encountered by 
circulating PBMC.  Abnormal cytokine profiles within these microenvironments could indeed 
alter signaling pathways.  Studies suggest that PBMC are disordered in number and function in 
the setting of cancer, suggesting that global immune function is compromised beyond the 
immediate tumor microenvironment.  These defects include a higher proportion of PBMC 
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undergoing spontaneous apoptosis and decreased zeta-chain expression [133, 134].    There are a 
number of ways in which aberrant signaling may occur specifically within the STAT and MAPK 
pathways.  For example, there could be an increased/decreased level of phosphorylation in the 
basal state or increased/decreased activation in response to cytokines. Recently a similar 
technique examined STAT1 phosphorylation in PBMC of melanoma patients following IFNα 
stimulation.  Unstimulated PBMC from melanoma patients had significantly less pSTAT1 than 
healthy controls, whereas pSTAT1 levels in IFNα stimulated cells were comparable [116].  Even 
though the magnitudes of cytokine-induced responses are normal, it is possible that the kinetics 
of phosphorylation are altered.   
As we have detected bimodal lymphocyte responses to various stimuli (e.g. IFNα, IL-7), 
we plan to assess discrete cell populations within PBMC by using antibodies against surface 
proteins, cell-specific markers, which will allow identification of signaling responses in subsets.  
In preliminary experiments, using the current permeabilization strategy, 90% methanol, many 
surface epitopes are compromised, thus unable to be stained.  Another manuscript is in the works 
to address these problems with permeabilization and detrimental effects on surface staining.  
Coupling cell surface or other intracellular markers can enable more sophisticated analysis of 
rare populations including PDCs and MDCs, as well as cells poorly able to be cryopreserved 
such as neutrophils and eosinophils.  Once the normal responses to individual cytokines have 
been identified within specific PBMC subpopulations, similar techniques can be used to analyze 
cells from patients with a variety of inflammatory states.  Before this can be done however, 
methods must be optimized to standardize quantitative flow cytometry.  Due to the technical 
simplicity, low number of cells required, and the ability to use banked, frozen PBMC, this flow-
cytometric technique is promising for use in the clinic as a diagnostic tool or to monitor immune-
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directed therapies. The combination of immunophenotyping with a rapid, cytometric assay to 
detect the integrity of signaling pathways will prove a valuable tool in dissecting out discrete cell 
populations within complex mixtures to assess individuals in the setting of both acute and 
chronic diseases [135] or following immunotherapy [136-138].  
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5.0 SIMULTANEOUS MEASUREMENT OF CELL SURFACE AND INTRACELLULAR 
PHOSPHORYLATED PROTEINS IN HUMAN PBMC 
 
 
 
5.1 ABSTRACT 
 
Phenotyping and simple enumeration of peripheral blood mononuclear cells (PBMC) is of 
limited value for the assessment of many clinical states.  As a preferred alternative, cell surface 
phenotyping may be combined with functional assays for enhanced assessment of altered cells 
circulating in patients. One simple, yet informative and rapid approach is to examine signaling 
within individual cells following brief periods of stimulation via flow cytometry.  Although 
monocytes and lymphoid cells can be distinguished based on size, current permeabilization 
strategies necessary for identifying intracellular phosphorylated signaling molecules largely 
compromise the labeling of cell surface proteins used to distinguish individual cellular subsets.  
We have successfully developed conditions that allow for simultaneous detection of cell surface 
proteins and intracellular phosphorylated proteins in human PBMC following rapid in vitro 
cytokine stimulation.  We analyzed permeabilized CD4, CD8, CD14, CD19, and CD56 
expressing cells together with intracellular pSTAT1, pSTAT3, pSTAT5, pSTAT6, pp38 MAPK, 
or pERK1/2 within total PBMC.  Of the permeabilizing conditions tested, 75% methanol enabled 
superior simultaneous detection of both cell surface and intracellular epitopes.  This method  
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enables the rapid functional analysis of subsets within complex cell mixtures and provides an 
opportunity for assessing abnormalities arising in the setting of acute or chronic inflammatory 
states. 
 
 
 
5.2 INTRODUCTION 
 
When compared with other functional assays, analysis of signaling pathways using antibodies 
directed against phospho-specific proteins provides a more rapid assessment of the functional 
state of immune cells [Montag DT, Lotze MT; submitted; [117]].  Western blotting has been 
typically used for cell signaling analysis, but this technique requires the use of large, 
homogenous populations of cells and is impractical for analysis of rare subpopulations, 
particularly within PBMC.  Additionally, this technique does not yield information at the single-
cell level. Flow cytometry can be utilized for the detection of phosphorylated proteins, which is 
quantitative, more rapid, and allows single cell analysis as a technique preferable to Western 
blotting.  Complex or rare populations of cells can be assessed without the need for additional 
cell separation [119, 120].  Qualitatively, flow cytometry and Western blotting provide similar 
results for phospho-protein analysis [69, 116].   
Protein phosphorylation is critical for the propagation of signals delivered by responses to 
pathogen [PAMP] or damage [DAMP] associated molecular pattern recognition as well as 
cytokine receptor ligation through pathways that ultimately mediate immunity.  These pathways 
are initiated by ligand-binding to specific receptors, which result in an almost immediate cascade 
of protein phosphorylation events.  The JAK/STAT and MAPK/ERK are two important families 
of signaling proteins that regulate immune responses, which are themselves propagated by 
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protein phosphorylation.  Host defense, growth control, and apoptosis are regulated through 
signals amplified by the JAK/STAT pathway [21, 26, 121].  In the setting of cancer, 
abnormalities in STAT signaling are commonly observed [33, 35, 122, 123].  Stress, 
inflammation, and other stimuli, initiate the MAPK/ERK pathway to regulate cell cycle 
progression, apoptosis, cytokine production, RNA splicing, and cell differentiation [24, 86, 87].  
Like the JAK/STAT family, MAPK/ERK signaling is dysfunctional in both stromal/immune 
cells as well as the epithelial components in many types of cancer [32, 34, 124, 125].     
The currently established means to analyze phospho-proteins by flow cytometry 
compromises antibody binding to several cell surface epitopes [69].  We adapted the current 
procedure to examine the normal signaling events within subsets of PBMC by simultaneously 
detecting cell-specific surface proteins and phosphorylated intracellular signaling proteins 
following a cytokine stimulus that has previously been determined to provide maximal 
phosphorylation.  Important members of the JAK/STAT and MAPK/ERK pathways including 
pSTAT1, pSTAT3, pSTAT5, pSTAT6, p-p38 MAPK, and pERK1/2 were evaluated within CD4, 
CD8, CD14, CD19, and CD56 expressing cells.  Additionally, the technique was assessed for its 
reproducibility within a healthy individual at different time points and in several healthy 
individuals simultaneously.  This strategy allows for rapid, reproducible detection of 
phosphorylated proteins within distinct cell populations within a complex mixture, which could 
be used to interrogate the signaling pathways of PBMC in patients.  This technique also enabled 
us to examine proximal signaling events and differential effects of cytokine treatment on major 
subpopulations of cells within the blood.  The reproducibility of this assay was favorable with 
substantial consistency from study to study, enabling it to serve now as a robust measure of 
individual cell types and immediate cytokine responsiveness/function.       
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5.3 MATERIALS AND METHODS 
 
5.3.1 Antibodies, cytokines, and fixation and permeabilization reagents 
  
Primary fluorophore-conjugated and unconjugated antibodies specific to phosphorylated 
proteins:  pSTAT1(Y701):Alexa 647, pSTAT1(Y701):PE, pSTAT3(Y705):Alexa 647, 
pSTAT5(Y694):Alexa 647, pSTAT5(Y694), pSTAT6(Y641):Alexa 647, 
pERK(T202/Y204):Alexa 647, and p-p38 MAPK(T180/Y182):Alexa 647, were purchased from 
BD PharMingen (San Diego, CA.)  Likewise, primary fluorophore-conjugated antibodies against 
cell-specific surface proteins: CD4:APC, CD4:PE, CD8:APC, CD8:PE, CD14:APC, CD19:PE, 
CD56:APC, and CD56:PE, were purchased from BD PharMingen (San Diego, CA.)  Antibodies 
to total STAT5 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA.)  Interferon 
(IFN)-αA, IL-4 (Biosource, Camarillo, CA), interferon (IFN)-γ, IL-2, IL-10 (R&D Systems Inc, 
Minneapolis, MN), and phorbol 12-myristate 13-acetate (PMA) (Sigma, St. Louis, MO) were 
used to induce phosphorylation in PBMC.  Cells were fixed using 2% paraformaldehyde (Fisher 
Scientific, Pittsburgh, PA.)  BSA (Spectrum Chemical, Gardena, CA), sodium azide, and saponin 
(Sigma, St. Louis, MO) were used to make 0.5% BSA/0.1% sodium azide/0.1% saponin in PBS 
(Fisher Scientific, Pittsburgh, PA) for cell permeabilization.  Alternatively, cells were 
permeabilized in varying concentrations of methanol (Fisher Scientific, Pittsburgh, PA), ethanol 
(Pharmco, Brookfield, CT), isopropanol (Acros Organics, Geel, Belgium) or acetone (Sigma, St. 
Louis, MO.)   
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5.3.2 Isolation of PBMC   
 
10mL of Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden) was pipetted into the 
bottom of a centrifuge tube containing 20 mL of whole blood and 20 mL of PBS.  The blood was 
spun at 400xG for 30 minutes.  PBMC were pipetted off into a new centrifuge tube.  The cells 
were spun into a pellet at 400xG for 10 minutes.  5 mL of ACK buffer (0.15M NH4Cl, 10mM 
KHCO3, 0.1mM NaEDTA; pH 7.2-7.4) was added to the cells for 15 minutes at RT to lyse 
remaining RBC.  The cells were pelleted and resuspended in IMDM (Mediatech, Herndon, VA).  
Cells were counted, spun, and resuspended in freeze medium at a concentration of 107 cells/mL.  
Freeze medium used to store PBMC consisted of 90% heat denatured FBS (Mediatech, Herndon, 
VA) and 10% DMSO (Fisher Scientific, Pittsburgh, PA).  107 PBMC were put into separate 
cryogenic vials (Corning, Corning, New York).  The PBMC were kept at -80°C for one day and 
were then transferred to a liquid nitrogen freezer.   
 
5.3.3 PBMC stimulation and phospho-protein staining   
 
PBMC were removed from liquid nitrogen and were thawed in a 37°C water bath.  The cells 
were washed in IMDM to remove the freeze medium.  5x105 cells in 50 μl were pipetted into 
separate wells of a 96-well polypropylene plate (Corning, Corning, NY.)  7 μl of primary-
conjugated antibody against cell surface proteins was incubated with the cells for 30 minutes at 
room temperature.  The cells were washed and resuspended in 50 μl of IMDM containing 
cytokines for stimulation for 15 minutes at 37°C.  We have previously determined the 
concentrations needed to achieve maximum phosphorylation in dose response experiments.  The 
concentrations of the cytokines used were as follows:  IFNα (100 IU/ml), IFNγ (1000 IU/ml), IL-
2 (1000 IU/ml), IL-4 (100 ng/ml), IL-10 (100 ng/ml), PMA (100 nM).  50 μl of 2% 
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paraformaldehyde was added to give a final concentration of 1% and was left at room 
temperature for 10 minutes to fix the cells.  The PBMC were washed in PBS to remove the 
fixative.  For permeabilization, several different strategies were employed.  Cells were either 
incubated with 200 μl of varying concentrations of methanol, ethanol, isopropanol, or acetone at 
-20°C for 10 minutes.  Alternatively, cells were permeabilized using 200 μl of 0.5% BSA/0.1% 
sodium azide/0.1% saponin in PBS at room temperature for 10 minutes.  Saponin-treated cells 
were washed in PBS/0.5% BSA/0.1% saponin, while the other treatment groups were washed in 
PBS.  The cells were resuspended in 50 μl of FACS buffer (10% FBS/0.1% sodium azide in 
PBS.)  7 μl of phospho-specific primary-conjugated antibody was added to each well and was 
left at room temperature for 30 minutes.  After incubation with antibody, the cells were washed 
in PBS + 0.2% Tween-20 for 10 minutes to eliminate non-specific binding.  Labeled cells were 
resuspended in 250 μl of FACS buffer in preparation for flow cytometry analysis.   
 
5.3.4 Western blotting of total and phospho-STAT   
 
PBMC are first magnetically separated into lymphocytes and monocytes using MACS CD14 
positive selection (Miltenyi Biotec, Auburn, CA.) according to the manufacturer’s suggestion.  
Monocytes and lymphocytes were either left untreated in IMDM or were treated with IL-2 at 
1000 IU/ml for 15 minutes.  Whole cell lysates were prepared by incubating the cells in lysis 
buffer (100 mM NaCl, 10 mM Tris (pH 87.4), 1% NP-40, phosphatase inhibitor cocktail I and II 
(Sigma, St. Louis, MO)) for 15 minutes.  Following lysis, a BCA assay (Pierece Biotechnology, 
Rockford, IL) was performed to analysis total protein concentration within each of the lysates.  
Lysates were boiled for 5 minutes in XT buffer (Bio-Rad Laboratories, Hercules, CA) containing 
10% β-mercaptoethanol.  The samples were loaded into Criterion XT precast gels (Bio-Rad 
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Laboratories, Hercules, CA) at 10μg per lane.  Proteins were separated by gel electrophoresis at 
100V for 1.5 hours.  The proteins were then transferred to nitrocellulose membranes (Bio-Rad 
Laboratories, Hercules, CA) at 100V for 45 minutes.  After blocking the membrane in TBS 
containing 1% BSA overnight at room temperature, the membrane was probed with mouse anti-
pSTAT5 at a 1:500 dilution for 1 hour at room temperature under constant agitation.  After three 
10 minutes washes with TBS containing 0.2% Tween-20, the blot was probed with HRP-
conjugated donkey-anti-mouse IgG at 10 ng/ml for 1 hour at room temperature under constant 
agitation.  The blot was washed three times with TBS containing 0.2% Tween-20.  Supersignal 
West Pico Chemiluminescence Substrate (Pierce Biotechnology, Rockford, IL) was added to the 
blot according to the manufacturer’s suggestion.  After the blot was exposed to x-ray film for 10 
minutes, the film was developed using a Kodak X-OMAT 2000A processor.  Following 
developing, the blot was incubated in stripping solution (2.5 pH, 0.2M glycine, 0.05% Tween-
20) at 80°C for 30 minutes.  To ensure that stripping was complete, the blot was washed in TBS 
three times, then re-incubated in chemiluminescence substrate and re-exposed to x-ray film.  The 
blot was re-probed for total STAT5 by first blocking the membrane at room temperature for one 
hour, then incubated rabbit anti-STAT5 at 1μg/ml at room temperature for one hour under 
constant agitation.  Then blot was washed three times with TBS containing 0.2% Tween-20.  
HRP-conjugated goat-anti-rabbit IgG at a concentration of 10ng/ml was incubated with the blot 
for one hour at room temperature under constant agitation.  The blot was washed three times 
with TBS containing 0.2% Tween-20.  Chemiluminescence substrate was added to the blot 
according to the manufacturer’s suggestions.  After the blot was exposed to x-ray film for 30 
seconds, it was developed. 
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5.3.5 Flow cytometric analysis of phospho-proteins   
 
A FACSArray (BD Bioscience, Franklin Lakes, NJ) was used for flow cytometric analysis.  The 
FACSArray was first calibrated using Sphero Rainbow fluorescent particles (BD Bioscience, 
Franklin Lakes, NJ).  After calibration, the 96-well plate containing the samples was placed into 
the instrument.  The instrument automatically compensated for optical spillover using three set-
up wells: one unlabeled, and two containing cells labeled with one of each of the fluorophores 
used.  A gate was created around populations that stained positive for labeled cell surface 
proteins.  Gates were also created around total lymphocyte and monocyte populations based on 
forward and side scatter intensities.  10,000 cells within the lymphocyte/monocyte gates were 
collected for each sample.  FACSDiva software (BD Bioscience, Franklin Lakes, NJ) was used 
for data acquisition and off-line analysis.  For each of the gated populations, the geometric mean 
fluorescence intensity was analyzed. 
 
 
 
5.4 RESULTS 
 
5.4.1 Effects of saponin and 90% methanol permeabilization on intracellular and cell 
surface labeling 
 
PBMC were either left untreated in IMDM or were treated with 100 IU/ml of IFNα for 15 
minutes at 37°C.  Following fixation, cells were either permeabilized with 0.1% saponin or 90% 
methanol as described in the materials and methods section.  All of the PBMC were labeled with 
anti-pSTAT1-PE.  Additionally, anti-CD4-APC, anti-CD8-APC, anti-CD14-APC, and anti-
CD56-APC were used to label untreated and treated cells in each permeabilization group.  Figure 
 85
14 shows the dot plots of pSTAT1-PE fluorescence intensity versus that of the cell surface 
proteins.  Quadrants have been set to gate on positive and negative populations.  The top two 
rows represent untreated cells permeabilized with either saponin or methanol.  It is readily 
apparent that saponin allows for better labeling of extracellular proteins than methanol, 
especially CD56 and CD14, but not for pSTAT1, as the upper quadrants are basically devoid of 
cells.  Methanol allows one to visualize cells that presumably have basally phosphorylated 
STAT1 in the untreated group, where approximately 30% are positive in the CD14 population.  
Following IFNα stimulation, a large increase in STAT1 phosphorylation is evident only in 
methanol permeabilized cells, as indicated in the bottom row of Figure 14.  With saponin 
permeabilization, there is no detectable change in activated STAT1.  Thus, we have concluded 
that methanol permeabilization is necessary for the detection of phosphorylated STAT1, but this 
technique is not optimal for staining of cell surface proteins. 
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Figure 14. Methanol is superior to saponin permeabilization for simultaneous 
staining of intracellular and cell surface proteins.  PBMC were untreated (upper two 
rows) or treated with 100 IU/ml of IFNα (bottom two rows) for 15 minutes at 37°C.  
Permeabilization was performed in 0.1% saponin or 90% methanol. Cells were labeled 
with APC-conjugated antibodies against CD8, CD56, CD4, or CD14 and with a PE-
conjugated antibody to pSTAT1.  CD14 labeled cells were collected in a monocyte gate, 
but all other cells were collected in a lymphocyte gate based on scatter.  Intracellular 
labeling is best accomplished with methanol, while saponin is superior for cell surface 
labeling 
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5.4.2 Use of a panel of different permeabilizing agents to enhance concurrent intracellular 
and cell surface detection 
 
Following 15 minutes of stimulation with 100 ng/ml of IL-4 or IMDM alone at 37° C, PBMC 
were fixed.  Cells were then permeabilized in varying concentrations of methanol, ethanol, 
isopropanol, or acetone for 10 minutes at -20°C.  Cells were labeled with both anti-pSTAT6-
Alexa 647 and anti-CD56-PE.  During flow cytometric acquisition, cells were divided into three 
gates: monocytes, lymphocytes, and CD56+, based on forward scatter, side scatter, and 
fluorescence intensity of CD56-PE.  As expected, the upper panel of Figure 15 indicates that the 
GMFI of CD56 within the CD56- populations (monocytes and lymphocytes) is low.  However, in 
the CD56+ population, as shown, there is a large amount of variation in the GMFI of CD56-PE 
for each individual permeabilizing agent applied.  Based on the upper figure, 70% methanol,  
50% ethanol, all isopropanol concentrations, and all concentrations of acetone except 100%, 
allow for suitable identification and resolution of CD56+ cells from negative cells.  Additionally, 
the effectiveness of pSTAT6 labeling was examined by plotting the relative difference in GMFI 
of pSTAT6 (GMFI of IL-4 stimulated cells minus GMFI of untreated cells) versus the three 
gated cell populations.  As shown in the lower panel of Figure 15, of the permeabilizing agents 
tested that enabled superior CD56 labeling, 70% methanol allows for maximal detection of 
pSTAT6.  In fact, the GMFI of pSTAT6 is comparable to the group permeabilized with 90% 
methanol in the monocyte population, which is the current method utilized for detecting 
phospho-proteins [69].  The asterisks in the CD56+ group indicate that insufficient cells were 
present to meaningfully assess the GMFI. 
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Figure 15. Marked differences in intracellular and cell surface staining of 
proteins are noted using a panel of permeabilizing agents.  PBMC were either 
untreated or treated with 100 ng/ml of IL-4 for 15 minutes at 37°C.  Cells were 
labeled with anti-CD56-PE and anti-pSTAT6-Alexa 647.  The gating used to 
identify CD56+ lymphocytes is indicated in panel A.  The lymphocyte gate in the 
upper panel is used to create the CD56 gates in the lower panel. Cell surface labeling 
efficiency is shown as GMFI of anti-CD56-PE versus a gated cell population 
(monocytes, CD56-, or CD56+ lymphocytes) for each permeabilization condition 
(panel B.)  Intracellular labeling efficiency is represented as the relative difference in 
GMFI (IL-4 treated minus untreated) of anti-pSTAT6 (panel C.)  Of the conditions 
tested, 70% methanol allowed for maximal simultaneous staining.   
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5.4.3 Varying methanol concentrations to improve simultaneous cell surface and 
intracellular labeling 
 
PBMC were treated identically as in the previous experiment, except the cells were 
permeabilized with a broader range of methanol concentrations alone at -20°C.  The upper panel 
of Figure 16 illustrates the effect that different methanol concentrations had on the GMFI of 
CD56-PE in the same three gated populations.  As was expected, the GMFI was very low in both 
CD56- populations.  There was a negative correlation between the GMFI of CD56-PE and 
methanol concentration in the CD56+ gate.  A distinct population of CD56+ cells was first 
identifiable at a concentration of 75% methanol and further dilutions.  In the lower panel of 
Figure 16, intracellular labeling is examined once again by plotting the relative difference in 
GMFI of pSTAT6 versus the three gated populations.    In a few cases, mainly with 0% methanol 
(PBS), i.e. not permeabilized, there were negative values for the relative difference in GMFI.   
This likely occurred because the auto-fluorescence of the untreated cells was greater than that of 
the IL-4 treated cells.  Within the monocyte gate, 90% methanol seemed to give a lower GMFI 
for pSTAT6 compared to slightly lower concentrations, but this is also likely due to untreated 
cells having higher autofluorescence.  At methanol concentrations of 70% or less, there is a 
decrease in the GMFI of pSTAT6 in both CD56- populations.  80-85% methanol allows for 
superior detection of pSTAT6, but these concentrations did not enable satisfactory labeling of 
CD56.  The asterisks in the lower panel indicate that these concentrations did not generate 
enough identifiable CD56+ cells to calculate a meaningful GMFI.  The next greatest GMFI in  
pSTAT6 occurs when 75% methanol was used, which also permitted a CD56+ population to be 
gated.  Considering these results, 75% methanol is the permeabilization condition of choice, 
enabling superior detection of both cell surface and intracellular proteins simultaneously. 
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Figure 16. 75% methanol enables simultaneous intracellular and cell 
surface labeling.  PBMC were either untreated or treated with 100 ng/ml of 
IL-4 for 15 minutes at 37°C.  Following permeabilization with varying 
concentrations of methanol, cells were labeled with anti-CD56-PE and anti-
pSTAT6-A647. GMFI of anti-CD56-PE versus a gated cell population 
(monocytes, CD56-, or CD56+ lymphocytes) is plotted for each 
permeabilization condition (upper panel.)  Intracellular labeling efficiency is 
represented as the relative difference in GMFI (IL-4 treated minus untreated) 
of anti-pSTAT6 (lower panel.)  To maximize both intracellular and cell surface 
labeling, 75% methanol appeared to give the best results.   
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5.4.4 Characterization of differential responses in protein phosphorylation in PBMC 
subtypes following cytokine stimulation 
 
In this set of experiments, PBMC were either left untreated in IMDM or were treated with IFNγ 
(1000 IU/ml), IL-10 (100 ng/ml), IL-2 (1000 IU/ml), IL-4 (100 ng/ml), or PMA (100 nM) for 15 
minutes at 37°C.  All of the cells were fixed, washed, and then permeabilized in 75% methanol 
for 10 minutes at -20°C.  Both untreated and cytokine stimulated cells were labeled with 
antibodies against anti-CD4-PE, anti-CD8-PE, anti-CD19-PE, or anti-CD56-PE.  Depending on 
which cytokine was used to treat the cells, untreated and treated PBMC were labeled with Alexa 
647-conjugated antibodies to STAT1, pSTAT3, pSTAT5, pSTAT6, pp38 MAPK, or pERK1/2.  
During analysis of individual phospho-proteins, there were four sets of untreated and cytokine-
treated cells except for pSTAT1 labeled cells due to low cells counts in the CD56 labeled group.  
Because monocytes were gated in each of these groups based on scatter properties alone, their 
results are represented as the mean of four comparable conditions including standard error bars.  
Figure 17 shows the mean GMFI of all the labeled phospho-proteins in both unstimulated and 
stimulated monocytes.  Treatment of PBMC with IL-2 or PMA did not appear to significantly 
increase the phosphorylation of STAT5 or p38 MAPK in monocytes.  The absence of STAT5 
phosphorylation in monocytes following IL-2 stimulation is confirmed by Western blot as well 
(Figure 19a.)  On the other hand, IFNγ, IL-10, IL-4, and PMA induced phosphorylation of 
STAT1, STAT3, STAT6, and ERK1/2 respectively in monocytes.   The error bar is large on the 
IFNγ treated cells, which is due to the mean being calculated from three rather than four samples 
and one outlier in the data.   
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Figure 17. Remarkable differences in individual phospho-proteins are 
detected in monocytes.  PBMC were untreated or treated with IFNγ (1000 IU/ml), 
IL-10 (100ng/ml), IL-2 (1000 IU/ml), IL-4 (100 ng/ml), or PMA (100nM) for 15 
minutes at 37°C.  All cells were permeabilized in 75% methanol.  Monocytes were 
gated based on scatter properties.  Cells were labeled with Alexa 647-conjugated 
antibodies against pSTAT1, pSTAT3, pSTAT5, pSTAT6, p38 MAPK, or ERK1/2.  
GMFI of monocytes was measured in four samples per condition and the standard 
deviation is included as error bars. 
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In Figure 18, lymphocytes are grouped into panels based on the phospho-protein being 
analyzed.  Within each panel the GMFI of the labeled phospho-protein is plotted against cells 
positive for CD19, CD4, CD8, or CD56.   IFNγ appears to have modest effects on STAT1 
phosphorylation in lymphocytes, CD4+ cells being the most responsive of the subsets examined.  
All PBMC subsets phosphorylated STAT3 in response to IL-10, CD19+ cells being the least 
responsive.  STAT5 was phosphorylated to the greatest degree in CD4+ cells, followed by CD8+ 
and CD56+ cells after IL-2 treatment.  In contrast, CD19+ cells appeared to be unresponsive to 
IL-2.  To confirm that STAT5 is indeed phosphorylated in lymphocytes following IL-2 
stimulation, a Western blot was performed.  Figure 19b clearly verifies that phosphorylated 
STAT5 is present only in IL-2 stimulated lymphocytes.  Following incubation with IL-4, all 
PBMC subsets increased STAT6 phosphorylation relatively equally.  Likewise, all groups of 
cells examined induced phosphorylation of ERK1/2 similarly following PMA treatment.  PMA 
stimulation also resulted in phosphorylation of p38 MAPK within all subsets tested, but only  
modestly within CD4+ cells.  Another observation taken from Figures 17 and 18 is that 
fluorescence in untreated cells labeled for pSTAT1 is higher than that of other phospho-proteins.  
This could be due to increased basal phosphorylation levels in STAT1 compared to other family 
members, suggesting some possible chronic release and exposure to interferon family members.  
At least for STAT5, Western blot confirms that there is basically no phosphorylation present in 
the unstimulated cells.  Additionally, fluorescence intensity is higher in untreated monocytes 
labeled for pp38 MAPK, likely due to increased basal activity as well. 
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Figure 18. Phospho-protein analysis reveals differential responsiveness of CD19+, 
CD4+, CD8+, and CD56+ cells to individual cytokines.  PBMC were untreated 
(unfilled bars) or treated with IFNγ (1000 IU/ml), IL-10 (100ng/ml), IL-2 (1000 
IU/ml), IL-4 (100 ng/ml), or PMA (100nM) (filled bars) for 15 minutes at 37°C.  The 
treatment that each group of cells received is in the upper left corner.  All cells were 
permeabilized in 75% methanol.  Cells were labeled with PE-conjugated antibodies to 
CD19, CD4, CD8, or CD56 and Alexa 647-conjugated antibodies to pSTAT1 (panel 
A), pSTAT5 (panel B), pERK (panel C), pSTAT3 (panel D), pSTAT6 (panel E), or 
pp38 (panel F.)  The GMFI of each labeled phospho-protein was plotted against cells 
gated positive for the labeled cell surface protein.  (ND) indicates not determined due 
to low cell counts.    
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Figure 19. Western blot confirms differential protein phosphorylation in distinct 
cell types.  PBMC were separated into monocytes and lymphocytes and were either 
treated with IL-2 or left untreated.  The amount of total STAT5 is comparable between 
monocytes/lymphocytes and does not change following IL-2 stimulation (panel A.)  
There is no basal phosphorylation of STAT5 within lymphocytes/monocytes and 
STAT5 is phosphorylated in lymphocytes alone following IL-2 stimulation (panel B), 
confirming previous results in figures 4 and 5 obtained by flow cytometry.  1: 
unstimulated lymphocytes; 2: IL-2 (1000 IU/ml) stimulated lymphocytes; 3: 
unstimulated monocytes; 4: IL-2 (1000 IU/ml ) stimulated monocytes. 
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5.4.5 Inter- and intra-individual variability in STAT phosphorylation 
 
For inter-individual variability experiments, PBMC were isolated from three different 
individuals on the same day.  For intra-individual variability experiments, PBMC were isolated 
from one individual three times over a course of ten months.  All cells were frozen, thawed on 
the same day, and used in the same experiment to evaluate STAT phosphorylation.  PBMC were 
either treated with IL-10 (100 ng/ml), IL-2 (1000 IU/ml), IFNα (1000 IU/ml) or left untreated in 
IMDM for 15 minutes at 37°C.  Following cytokine stimulation and fixation, cells were 
permeabilized in 75% methanol as noted above.  Untreated and treated cells were labeled with 
Alexa 647-conjugated antibodies to pSTAT1, pSTAT3, or pSTAT5.  Additionally, cells were 
labeled with PE-conjugated antibodies against CD4, CD8, CD19, or CD56.   
In Figure 20, inter-individual variability is represented by plotting the GMFI of each 
labeled phospho-STAT for each individual within a positive-gated subset of cells.  Monocytes 
were gated based on scatter properties.  In agreement with previously shown data, following IL-2 
treatment, STAT5 is not phosphorylated in the monocyte or CD19+ populations of all 
individuals.  Also in agreement with previous data, STAT5 is phosphorylated primarily within 
the CD4+ population, followed by CD8+ and CD56+ populations.  After treatment with IL-10, 
STAT3 is phosphorylated in all cell types examined, but predominantly within the monocytes. 
There is some variability in individual responses, but referring to Table 2, the CVs are less than 
20 for most of the treatment conditions.  It is interesting to note that one healthy individual 
consistently had lower levels of phosphorylation in both STAT proteins in all PBMC subsets 
tested. 
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Figure 20. Modest inter-individual variability in protein phosphorylation.   
PBMC were isolated from three different individuals on the same day.  The cells were 
untreated or treated with IL-2 (1000 IU/ml) or IL-10 (100 ng/ml) for 15 minutes at 
37°C.  Gates were set on monocytes (panel A) based on scatter properties and cells 
positively labeled for CD8 (panel B), CD56 (panel C), CD4 (panel D), and CD19 
(panel E.)  Within these gates, GMFIs of labeled pSTAT5 and pSTAT3 were 
measured.  Different shapes encoded in the legend represent the three subjects. 
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Table 2. Multiple donor variability in STAT phosphorylation.  This table 
summarizes the results in Figure 20.  The GMFI was averaged for labeled pSTAT5 
and pSTAT3 in unstimulated and stimulated cells from all three donors and the 
coefficient of variance was calculated. 
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The results of the intra-individual variability experiment are shown in Figure 21 with the 
dates of each draw included in the legend.  The amount of time that cells spent frozen did not 
seem to correlate with responsiveness, as cells frozen the longest were usually most responsive 
and cells frozen the shortest amount of time had intermediate responsiveness.  Once again, the 
relative responsiveness of the cells appeared to be consistent within each cell type and for each 
STAT protein.  When compared to STAT3, STAT1 phosphorylation levels appear to be higher in 
untreated cells, which were observed in previous experiments as well.  Similar to the inter-
individual variability, the CVs for STAT phosphorylation within a single individual were mostly 
less than 20, as indicated in Table 3.  There were large CVs in STAT1 phosphorylation in 
untreated monocytes and CD19 cells and IFNα-treated cells within CD4 and CD19 subsets, 
suggesting some heterogeneity of responsiveness.  Likewise, CVs were also somewhat high for 
pSTAT3 in IL-10 treated CD19 and CD56 cells.  These differences could be of modest 
importance if larger sample sizes [which we are now examining in patients with melanoma on 
immunotherapy regimens] were obtained. 
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Figure 21. Limited intra-individual variability in protein phosphorylation.  
PBMC were isolated three times from a single individual over ten months.  The 
cells were untreated or treated with IL-10 (100 ng/ml) or IFNα (1000 IU/ml) for 15 
minutes at 37°C. Gates were set on monocytes (panel A) based on scatter 
properties and cells positively labeled for CD8 (panel B), CD56 (panel C), CD4 
(panel D), and CD19 (panel E.)  Within these gates GMFIs of labeled pSTAT3 and 
pSTAT1 were measured.  The dates of the blood draws are included next to the 
shapes in the legend. 
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Table 3. Single donor variability in STAT phosphorylation.  This table summarizes
the results in Figure 21.  The GMFI was averaged for labeled pSTAT3 and pSTAT1 in 
unstimulated and stimulated cells from each of the three blood draws and the 
coefficient of variance was calculated.    
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5.5 DISCUSSION 
 
Our objective was to develop a robust methodology to detect activated signaling pathways within 
all major PBMC subpopulations by simultaneously staining cell-specific surface epitopes and 
intracellular phosphorylated proteins for flow cytometry.  By using a flow cytometric strategy, 
evaluation and set-up time is greatly reduced and fewer cells are required when compared with 
alternative techniques including Western blotting.  Western blotting and flow cytometry provide 
similar qualitative results for phospho-protein analysis [19, 69, 116], as we have also 
demonstrated in this report.  Flow cytometry, however, offers greater sensitivity and allows one 
to identify individual cells with differences in responsiveness, rather than a mean value for the 
total cell population without separating cells prior to stimulation and analysis.   
We began by comparing saponin permeabilization, which is a standard technique for 
labeling many intracellular proteins [17, 139], to 90% methanol, which was recently established 
for staining of phosphorylated proteins [69].  In saponin treated cells, detection of 
phosphorylated proteins was severely impaired, however labeling of surface proteins improved.  
With 90% methanol treatment, CD14 and CD56 positive cells were virtually undetectable.  Thus, 
it appears that methanol compromises the labeling of surface epitopes given currently available 
commercial antibodies, some more than others, while saponin is unable to allow staining 
antibodies access to intracellular phosphorylated epitopes.   
When permeabilized with acetone and a panel of alcohols at varying concentrations, the 
phospho-protein signal was greatest at higher concentrations, whereas surface protein staining 
decreased.  Of the permeabilizing conditions tested, methanol provided maximal detection of 
phosphorylated proteins.  Based on this, we permeabilized cells with a broader range of methanol 
concentrations to maximize both intracellular and cell surface labeling.  75% methanol provided 
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an increase in the detection of surface protein, CD56, and staining of phospho-protein equivalent 
to 90% methanol.  This concentration seems to be sufficient to expose the phosphorylated 
epitope within cells while limiting detrimental effects to surface epitopes.  In addition, 
phosphorylation patterns were consistent with previous studies of dose and timing of 
responsiveness of individual populations as we have previously reported. 
This technique resulted in low variability when applied to a single, healthy donor at 
different time points or several, healthy donors at a single time point.  The CV for the level of 
activated signaling protein was less than 20% in most cases for both treated and untreated cells.  
The relatively low levels of variability associated with this method hold promise that differences 
in cellular responsiveness will be detected between healthy individuals and those with abnormal 
signaling pathways in various disorders.       
The conditions that we developed enabled us to visualize the differential effects of 
cytokines on signaling proteins within major subpopulations of PBMC, which were gratifying 
and quite substantial.  One can imagine that this technique may also be readily applied to rare 
populations of cells, such as mDCs and pDCs.  In acute and chronic inflammation and cancer, 
our studies and others suggest that PBMC are disordered in both their number and function [133, 
134, 140, 141].  Dysfunctional signaling could result from persistent cytokine release, 
homeostatic inhibition mediated by suppressor of cytokine signaling [SOCS] proteins, other 
proteins elicited within pathological environments, or by pathogens interfering with normal 
signaling.  Because of the ease with which this technique is performed and the availability of 
blood samples from patients, this technique holds promise to enumerate specific cell populations 
from patients while evaluating their functional integrity in a clinical laboratory.  By detecting  
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abnormal cell populations and some of the changes in responsiveness to cytokine signals, this 
method can also be used potentially to enable and monitor pharmacologic intervention and 
treatment, as well as monitor response to treatment.   
We have described here a simple and easily applied technique to simultaneously detect 
surface epitopes and intracellular phosphorylated signaling proteins within PBMC by flow 
cytometry.  The ability to use banked, frozen PBMC enables this flow-cytometric technique to be 
readily applied in the clinic as a diagnostic tool or to monitor effects of immunosuppressive or 
immunostimulatory reagents such as FK506, cyclosporine, rapamycin, IL-2, CTLA4 antibody, 
and possibly pathogen or damage associated molecular pattern molecules [PAMPs/DAMPs] 
including HMGB1[132] or CpG molecules.  Furthermore, this technique is clinically applicable 
due to its technical simplicity and the low number of cells required for analysis.  We conclude 
that combining immunophenotyping with a rapid, cytometric assay to detect the integrity of 
signaling pathways is a remarkably valuable tool in assessing discrete cell populations within 
complex mixtures in the setting of both acute and chronic diseases including autoimmunity and 
cancer.  
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6.0 SUMMARY AND FUTURE DIRECTIONS 
 
 
 
As demonstrated here, a flow cytometric-based assay is a rapid and robust platform for 
measuring activated signaling pathways within a complex mixture of cells.  We were able to 
identify cytokines, as well as their most effective concentrations and duration of application that 
elicit maximal phosphorylation of a number of target signaling proteins within the JAK/STAT 
and MAP kinase pathways including STAT1, STAT3, STAT5b, STAT6, ERK1/2, and p38 
MAPK.  By manipulating the permeabilization conditions, we were able to successfully stain for 
intracellular phosphorylated proteins in combination with cell surface proteins used to identify 
subpopulations of PBMC, such as CD4, CD8, CD14, CD19, and CD56, which we have 
published [142].  Furthermore, this technique afforded the ability to examine differential 
phosphorylation within distinct cell types following application of identical stimuli, even without 
dual cell surface/intracellular staining, but by gating on lymphocytes and monocytes based on 
their intrinsic forward and side scatter properties.  Lastly, the technique developed herein 
resulted in a relatively low degree of variability when applied to PBMC from multiple 
individuals, as well as PBMC acquired from a single individual at different time points.  These 
findings strengthen our belief that this approach will be useful for identifying differences 
between healthy individuals and those with disease.   
Taken together, these results illustrate that flow cytometric measurement of activated 
signaling pathways is a powerful technique to rapidly analyze function within subsets of cells 
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comprising complex populations without excessive manipulation and separation.  Additionally, 
the results obtained by flow cytometry are qualitatively comparable to those acquired by the 
more time-consuming bulk analysis method, Western blotting.  Because our technique uses 
PBMC, which is a readily attainable source of cells, and the protocol is extremely rapid, it is very 
likely that this method will be of utility to scientists to define abnormalities in signaling within 
the setting of various inflammatory conditions, including cancer, rheumatoid arthritis [143, 144], 
inflammatory bowel disease [140, 145, 146], systemic lupus erythematosus [147], and infectious 
diseases.  Furthermore, once these disease-specific differences have been established, it may 
even be used as a diagnostic tool, where certain disorders are associated with an activation 
signature, meaning a defined group of proteins are abnormally phosphorylated in the context of a 
particular disorder.  To increase the likelihood of finding differences in activation between 
normal and disease states, protein microarrays using PSSAs could be utilized prior to the flow 
cyotmetric analysis.  In this way, the array could be used to rapidly screen a large number of 
phosphorylated proteins to identify potential targets.  Thereafter, the assay developed in this 
thesis could be used to pinpoint the aberrant cell type and its frequency.  Without much further 
development, flow cytometric analysis of phosphorylated proteins could be applied to 
therapeutic monitoring, such as administration of IL-2 and subsequent analysis of STAT5 
phosphorylation or blood could be drawn over the course of treatment to see if abnormal 
activation has subsided. 
At this point, little is known about the effects of factors such as age, obesity, smoking, or 
gender on phosphorylation events in signaling pathways.  Before utilizing this technique to 
analyze clinical samples, it should be applied to a much larger, diverse population of disease-free 
individuals to first define normal phosphorylation levels and their variability, both in basal and 
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cytokine-perturbed states.  This should illuminate any differences in signaling due to 
environmental, gender, or age-related factors.  Alternatively, phospho-signaling pathways could 
be analyzed directly between different groups of individuals to determine if the aforementioned 
factors indeed alter phosphorylation events.  Another option to avoid any environmental 
influences is to use samples taken from the same individual before and after therapy, which is 
what we have done in the following initial study.   
As a preliminary study to apply our developed methodology to a clinical disorder, we 
evaluated STAT1, STAT3, STAT5b, STAT6, p38 MAPK, and ERK phosphorylation, pre- and 
post in vitro stimulation with cytokines, within total PBMC isolated from stage IV melanoma 
patients before and after combined anti-CTLA4/IL-2 therapy.  We received cells from 13 
patients at points before and after therapy with roughly an equal number of patients either not 
responding, partially responding, or completely responding to therapy.  Of these patients, some 
also developed autoimmunity.  Our analysis objectives were to determine if combined anti-
CTLA4/IL-2 therapy, or the presence of tumor or autoimmunity affects the baseline activation 
state of PBMC and/or the ability of PBMC to respond to stimuli.  To negate the influence of cell 
viability on differences in phosphorylation, we measured cell viability by annexin V and Sytox 
orange staining prior to fixation.  We analyzed responses within lymphocytes and monocytes by 
gating on forward and side scatter, as well as within CD4+ lymphocytes, by including a 
fluorophore-conjugated antibody to CD4.   Many of the samples were analyzed in triplicate to 
improve statistical analysis.  Since there were roughly 72 samples for each phospho-protein 
target, giving a total of approximately 432 samples, we required the assistance of statisticians for 
analysis.  Based on data obtained from literature, we would expect to observe differences in 
phosphorylation in the presence of melanoma or in autoimmunity, as abnormal levels of 
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cytokines, growth factors, and endogenous danger signals are commonly detected in the serum.  
We have had a preliminary meeting to go over the results of the statistical analysis, which are 
premature to include in this thesis.  There are some provocative early notions that should be 
noted: All patients demonstrated greater IL-10 responsiveness following therapy, but this was 
especially noteworthy in the patients with autoimmunity.  Indeed the pSTAT3 response to IL-10 
was substantially less in those with complete responses to clinical therapy when comparing 
pretreatment and late responses.  IL-2, one of the agents that they were clinically treated with, 
promotes STAT5 responses and there appeared to be enhanced responsiveness following therapy 
in those with autoimmunity, as did phospho-p38 in response to phorbol ester stimulation in 
CD4+ cells. Given the relatively small patient numbers these results will need to be confirmed in 
a greater number of patients.       
In our studies, the number of parameters was limited to two, a cell surface protein to 
identify a subset of cells, and an intracellular phosphorylated protein.  Since we are using a flow 
cytometric method, additional parameters can easily be added, such as antibodies toward 
negative regulators of signaling.  Although these studies were performed on peripheral blood 
cells, the methodology should be applicable to many other cell types, especially those within 
complex mixtures including aspirates from solid tumors.  Furthermore, due to the evolution of 
robotics, this technique could possibly become fully automated in the future.  Through the use of 
automated liquid handling systems, such as the Biomek FX, it would be possible to perform all 
of the upfront sample preparation, including cytokine stimulation, fixation, permeabilization, and 
labeling without manual involvement.  Additionally, robotics could also load barcoded culture 
plates containing samples into already automated flow cytometers.  By including robotics and 
automation, it should be possible to increase the high-throughput nature of the technology, as 
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well as possibly limit sample variability caused by inaccuracies associated with manual pipetting 
and sample preparation.  In summary, the methods developed in this thesis provide an excellent 
stepping-stone for more in-depth studies regarding cell activation and its involvement in disease.  
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Figure 22. Flow cytometry and Western blot provide similar results for 
IL-2 dose-dependent STAT5 phosphorylation.  Lymphocytes and 
monocytes were left untreated or were treated with increasing concentrations 
of IL-2 as indicated.  In panel A, bands from figure 10A were analyzed by 
ImageJ densitometry software and the integrated pixel intensities were plotted.  
In panel B, median GMFIs of pSTAT5-A647 from figure 10A are plotted.  
There is a contribution of autofluorescence when obtaining data by flow 
cytometry, as indicated in the monocytes and untreated lymphocytes.  Both 
flow and Western blotting provide qualitative results.   
A B 
Figure 23. Flow cytometry and Western blot provide similar results for IL-2 
time-dependent STAT5 phosphorylation.  Lymphocytes and monocytes were 
left untreated or were treated with 1000 IU/ml of IL-2 for the indicated time 
intervals.  In panel A, bands from figure 10B were analyzed by ImageJ 
densitometry software and the integrated pixel intensities were normalized to 
total STAT5 and plotted.  In panel B, median GMFIs of pSTAT5-A647 from 
figure 10B are plotted.  There is a contribution of autofluorescence when 
obtaining data by flow cytometry, as indicated in the monocytes and untreated 
lymphocytes.  Furthermore, it appears that there is artifactually increased 
phosphorylation in untreated monocytes, presumably due to increased 
manipulation in Western blotting.  Upon IL-2 treatment, there is no increase in 
pSTAT5 in monocytes, but only in lymphocytes.  Both flow and Western 
blotting provide qualitative results.   
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